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The translational controlled tumour protein TCTP: Biological functions
and regulation
Abstract

The Translational Controlled Tumour Protein TCTP (gene symbol TPT1, also called P21, P23, Q23, fortilin
or histamine-releasing factor, HRF) is a highly conserved protein present in essentially all eukaryotic
organisms and involved in many fundamental cell biological and disease processes. It was first discovered
about 35 years ago, and it took an extended period of time for its multiple functions to be revealed, and even
today we do not yet fully understand all the details. Having witnessed most of this history, in this chapter, I
give a brief overview and review the current knowledge on the structure, biological functions, disease
involvements and cellular regulation of this protein. TCTP is able to interact with a large number of other
proteins and is therefore involved in many core cell biological processes, predominantly in the response to
cellular stresses, such as oxidative stress, heat shock, genotoxic stress, imbalance of ion metabolism as well as
other conditions. Mechanistically, TCTP acts as an anti-apoptotic protein, and it is involved in DNA-damage
repair and in cellular autophagy. Thus, broadly speaking, TCTP can be considered a cytoprotective protein. In
addition, TCTP facilitates cell division through stabilising the mitotic spindle and cell growth through
modulating growth signalling pathways and through its interaction with the proteosynthetic machinery of the
cell. Due to its activities, both as an anti-apoptotic protein and in promoting cell growth and division, TCTP
is also essential in the early development of both animals and plants. Apart from its involvement in various
biological processes at the cellular level, TCTP can also act as an extracellular protein and as such has been
involved in modulating whole-body defence processes, namely in the mammalian immune system.
Extracellular TCTP, typically in its dimerised form, is able to induce the release of cytokines and other
signalling molecules from various types of immune cells. There are also several examples, where TCTP was
shown to be involved in antiviral/antibacterial defence in lower animals. In plants, the protein appears to have
a protective effect against phytotoxic stresses, such as flooding, draught, too high or low temperature, salt
stress or exposure to heavy metals. The finding for the latter stress condition is corroborated by earlier reports
that TCTP levels are considerably up-regulated upon exposure of earthworms to high levels of heavy metals.
Given the involvement of TCTP in many biological processes aimed at maintaining cellular or whole-body
homeostasis, it is not surprising that dysregulation of TCTP levels may promote a range of disease processes,
foremost cancer. Indeed a large body of evidence now supports a role of TCTP in at least the most
predominant types of human cancers. Typically, this can be ascribed to both the anti-apoptotic activity of the
protein and to its function in promoting cell growth and division. However, TCTP also appears to be involved
in the later stages of cancer progression, such as invasion and metastasis. Hence, high TCTP levels in tumour
tissues are often associated with a poor patient outcome. Due to its multiple roles in cancer progression,
TCTP has been proposed as a potential target for the development of new anti-cancer strategies in recent pilot
studies. Apart from its role in cancer, TCTP dysregulation has been reported to contribute to certain
processes in the development of diabetes, as well as in diseases associated with the cardiovascular system.
Since cellular TCTP levels are highly regulated, e.g. in response to cell stress or to growth signalling, and
because deregulation of this protein contributes to many disease processes, a detailed understanding of
regulatory processes that impinge on TCTP levels is required. The last section of this chapter summarises our
current knowledge on the mechanisms that may be involved in the regulation of TCT
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Chapter 4

The Translational Controlled Tumour Protein
TCTP: Biological Functions and Regulation
Ulrich-Axel Bommer

Abstract The Translational Controlled Tumour Protein TCTP (gene symbol
TPT1, also called P21, P23, Q23, fortilin or histamine-releasing factor, HRF) is a
highly conserved protein present in essentially all eukaryotic organisms and
involved in many fundamental cell biological and disease processes. It was first
discovered about 35 years ago, and it took an extended period of time for its
multiple functions to be revealed, and even today we do not yet fully understand
all the details. Having witnessed most of this history, in this chapter, I give a brief
overview and review the current knowledge on the structure, biological functions,
disease involvements and cellular regulation of this protein.
TCTP is able to interact with a large number of other proteins and is therefore
involved in many core cell biological processes, predominantly in the response to
cellular stresses, such as oxidative stress, heat shock, genotoxic stress, imbalance of
ion metabolism as well as other conditions. Mechanistically, TCTP acts as an antiapoptotic protein, and it is involved in DNA-damage repair and in cellular
autophagy. Thus, broadly speaking, TCTP can be considered a cytoprotective
protein. In addition, TCTP facilitates cell division through stabilising the mitotic
spindle and cell growth through modulating growth signalling pathways and
through its interaction with the proteosynthetic machinery of the cell. Due to its
activities, both as an anti-apoptotic protein and in promoting cell growth and
division, TCTP is also essential in the early development of both animals and
plants.
Apart from its involvement in various biological processes at the cellular level,
TCTP can also act as an extracellular protein and as such has been involved in
modulating whole-body defence processes, namely in the mammalian immune
system. Extracellular TCTP, typically in its dimerised form, is able to induce the
release of cytokines and other signalling molecules from various types of immune
cells. There are also several examples, where TCTP was shown to be involved in
antiviral/antibacterial defence in lower animals. In plants, the protein appears to
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have a protective effect against phytotoxic stresses, such as flooding, draught, too
high or low temperature, salt stress or exposure to heavy metals. The finding for the
latter stress condition is corroborated by earlier reports that TCTP levels are
considerably up-regulated upon exposure of earthworms to high levels of heavy
metals.
Given the involvement of TCTP in many biological processes aimed at
maintaining cellular or whole-body homeostasis, it is not surprising that
dysregulation of TCTP levels may promote a range of disease processes, foremost
cancer. Indeed a large body of evidence now supports a role of TCTP in at least the
most predominant types of human cancers. Typically, this can be ascribed to both
the anti-apoptotic activity of the protein and to its function in promoting cell growth
and division. However, TCTP also appears to be involved in the later stages of
cancer progression, such as invasion and metastasis. Hence, high TCTP levels in
tumour tissues are often associated with a poor patient outcome. Due to its multiple
roles in cancer progression, TCTP has been proposed as a potential target for the
development of new anti-cancer strategies in recent pilot studies. Apart from its role
in cancer, TCTP dysregulation has been reported to contribute to certain processes
in the development of diabetes, as well as in diseases associated with the cardiovascular system.
Since cellular TCTP levels are highly regulated, e.g. in response to cell stress or
to growth signalling, and because deregulation of this protein contributes to many
disease processes, a detailed understanding of regulatory processes that impinge on
TCTP levels is required. The last section of this chapter summarises our current
knowledge on the mechanisms that may be involved in the regulation of TCTP
levels. Essentially, expression of the TPT1 gene is regulated at both the transcriptional and the translational level, the latter being particularly advantageous when a
rapid adjustment of cellular TCTP levels is required, for example in cell stress
responses. Other regulatory mechanisms, such as protein stability regulation, may
also contribute to the regulation of overall TCTP levels.

4.1

Introduction

Despite there being more than 300 scientific publications on ‘TCTP’ that have been
published on this protein over a period of 35 years, it is still difficult to give a brief,
comprehensive statement on its functional importance. Typically, papers on this
protein start with a sentence such as: ‘TCTP is a highly-conserved, multifunctional
protein involved in important biological and disease processes.’ This reflects the
fact that by now, many functional aspects of this protein have been revealed, many
of which are highly relevant to core biological and medical problems. The recent
increasing interest in this protein is also reflected by the fact that 15 review articles
on TCTP have already been published, all but two (Bommer and Thiele 2004;
Telerman and Amson 2009) within the last 5 years. However, most of these articles
focus on specific aspects of the TCTP literature, and they are spread over a wide
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range of journals. I feel therefore it is a very worthwhile undertaking by Amson and
Telerman to assemble this new collection of up-to-date reviews into one single
book. It should be a useful guide for the still growing ‘TCTP community’, which
currently comprises research groups from about 25 countries.

4.1.1

The ‘Translationally Controlled Tumour Protein
TCTP’: Names and History

The ‘TCTP story’ had a humble beginning with less than ten papers published
during the 1980s by three research groups, all interested in protein synthesis and in
the hunt for translationally controlled proteins. Initially, the protein was termed
according to its approximate molecular mass as Q23 (G. Thomas, Basel; Thomas
et al. 1981), P21 (G. Brawermann, Boston; Yenofsky et al. 1982) or as P23
(H. Bielka, Berlin-Buch; Bohm et al. 1989). At this time, the function of the protein
was completely unknown, and its most distinguished property was the ability to be
rapidly up-regulated upon growth induction of serum-starved murine cells, in a
manner insensitive to inhibition by actinomycin D (Thomas et al. 1981; Bohm et al.
1989). Even the publication of the first cDNA sequences of mouse P21 (Chitpatima
et al. 1988) and of its human homologue (Gross et al. 1989) did not shed any light
on its possible function, as the derived amino acid sequence did not display
similarity to any other known protein sequence, and since then, the protein is listed
in the databases as a separate ‘family’. It was in the latter publication (Gross et al.
1989) that the name ‘translationally controlled tumour protein’ was coined, since
the cDNA sequence had been derived from a human mammary carcinoma.
The first report on a functional association of TCTP appeared in 1995. Susan
MacDonald and co-workers (Baltimore) identified an extracellular function of this
protein as ‘histamine-releasing factor’ (HRF) present in biological fluids of allergic
patients (MacDonald et al. 1995). This discovery led to a series of studies exploring
the extracellular signalling function of HRF/TCTP in allergic and inflammatory
responses, as recently reviewed by Dr. MacDonald (2012a, b).
The first studies on intracellular functions of TCTP reported its Ca2+-binding
activity (Haghighat and Ruben 1992) and its microtubule association. Our study
revealed that TCTP/P23 is bound to microtubules, inclusive of the mitotic spindle,
in a cell-cycle-dependent manner, and that it has microtubule-stabilising activity
(Gachet et al. 1999). Subsequently, a whole array of additional interaction partners
of TCTP/HRF have been identified (reviewed in Kawakami et al. 2012; Bommer
2012; Acunzo et al. 2014).
Another milestone in the unravelling of TCTP’s function was the demonstration of
its anti-apoptotic activity by Ken Fujise’s group (Houston) (Li et al. 2001), exactly
20 years after its initial discovery (Thomas et al. 1981; Yenofsky et al. 1982). Based
on their findings, these authors invented the name ‘fortilin’ for this protein. Their
discovery led to a large number of additional studies on the cytoprotective role of
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TCTP/fortilin, which showed that the protein is rapidly up- (or down-)regulated in
response to a wide array of cellular stresses and that it is involved in a range of
cellular defence pathways (reviewed in Bommer 2012; Acunzo et al. 2014).
Despite its name, a convincing demonstration that TCTP is implicated in cancer
came only relatively late. Instrumental in this was the experimental ‘tumour
reversion model’ developed by the Telerman group (Telerman and Amson 2009;
Tuynder et al. 2002, 2004). Naturally, the cancer aspect of TCTP’s ‘function’ has
recently attracted increasing attention, as documented by the about 40 papers and
6 review articles (Telerman and Amson 2009; Bommer 2012; Acunzo et al. 2014;
Amson et al. 2013, 2011; Chan et al. 2012a; Efferth 2006; Koziol and Gurdon 2012)
on ‘TCTP and cancer’ that appeared only within the last 10 years.
Further additions to the complex story of the naming of this protein are in reports
on TCTP orthologues in non-vertebrate animals, lower eukaryotes and plants.
Typically, in these papers, a two-letter suffix before ‘TCTP’ indicates the species,
from which the protein sequence was derived (see Gutierrez-Galeano et al. (2014)
for an example). The yeast orthologue of TCTP was named ‘microtubule and
mitochondria interacting protein’ (Mmi1p) (Rinnerthaler et al. 2006), but in another
paper, it was also identified as the ‘translation-machinery-associated protein 19’
(TMA19) (Fleischer et al. 2006), and yet the gene symbol in yeast is YKL056c. In
contrast, the gene symbol in higher eukaryotes is TPT1, for ‘tumour protein,
translationally controlled-1’ (Thiele et al. 2000).

4.1.2

Gene Structure and mRNA

The first structure of a TPT1 gene (for rabbit) was characterised in Bernd Thiele’s
group in Berlin; the gene was found to comprise about 4000 nucleotides, beginning
at the transcription start site, and to consist of 6 exons and 5 introns, where the last
exon comprises the entire 30 -UTR of the mRNA (Thiele et al. 1998). A very similar
structure was also reported for the mouse (Fiucci et al. 2003) and the human
(Andree et al. 2006) TPT1 gene. The latter has been mapped to chromosome 13,
q12-->q14 (MacDonald et al. 1999), the mouse gene to chromosome 14 (Fiucci
et al. 2003) and the pig TPT1 gene to chromosome 11 (Yubero et al. 2009), in a
genomic context that is similar to that of the human chromosomal location.
The promoter regions of the active TPT1 gene were further investigated for the
rabbit (Thiele et al. 1998), mouse (Fiucci et al. 2003) and human (Andree et al.
2006) genes. They displayed a large number of transcription factor-binding motifs,
i.e. 10–15 motifs within the 450 nucleotides adjacent to the transcription start site.
Of these, seven motifs were conserved between all five mammalian species
inspected, and the activity of the tandem CREB transcription factor-binding site
was experimentally demonstrated for the human TPT1 gene (Andree et al. 2006).
The early characterisation and mapping of the TPT1 gene was complicated by
the fact that there is a considerable number of processed or unprocessed
pseudogenes in mammalian genomes, which is apparently not the case in lower
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eukaryotes, fungi, plants and non-mammalian animals (Hinojosa-Moya et al. 2008).
Several of these pseudogenes have been studied in some detail in the rabbit (Thiele
et al. 2000) and in mouse (Fiucci et al. 2003), and only few were found to have the
potential to produce a protein product.
Northern blot analysis of TCTP mRNAs from a range of different tissues
revealed that all cells produce two different TCTP mRNA species in both rabbits
(Thiele et al. 2000) and in humans (Andree et al. 2006), the longer one bearing a
320 nucleotide extension at the 30 -end, which is generated by an additional
polyadenylation site. These two isoforms comprise a total of about 800 and 1200
nucleotides, respectively (Andree et al. 2006). The ratio between the two mRNA
species differs considerably between different tissues, but the short mRNA is
always in excess (Thiele et al. 2000). The importance for the production of these
two different mRNA species has not yet been elucidated, but interestingly, in mouse
tissues, there was only one TCTP mRNA isoform detected (Fiucci et al. 2003).
Mammalian TCTP mRNAs contain an open reading frame of 519 nt (172 amino
acids), a 50 -UTR of about 100 nt and a 30 -UTR of about 200 nt or of 520 nt for the
longer isoform (Thiele et al. 2000). A particular feature of TCTP mRNAs, indicative for translational regulation, is a 50 -terminal oligopyrimidine tract (50 -TOP):
sequence 50 -CTTTTCCG . . . for the human, mouse and rabbit mRNAs (Thiele et al.
1998, 2000; Fiucci et al. 2003). The 50 -TOP motif is a hallmark for a specific group
of mRNAs that are under translational control through the mTOR complex
1 (mTORC1) signalling pathway (Meyuhas and Kahan 2015; Yamashita et al.
2008). We have recently demonstrated that growth induction of TCTP expression
is indeed regulated through this pathway (Bommer et al. 2015).
A second feature is the high CG-content in the 50 -UTR (about 80% in the mouse
sequence), which indicates the potential of the molecule to form a high degree of
secondary structure. Our lab has indeed shown that full-length TCTP mRNA of the
mouse is a very structured molecule, the structure formation being dependent on the
presence of the 50 - and the 30 -UTR. Consequently, the full-length mRNA molecule
is poorly translated, in contrast to a truncated version devoid of the 50 - and 30 -UTRs
(Bommer et al. 2002). Yet another feature is the presence of several AUUUA
elements in the 3’-UTR of the TCTP mRNA (Gross et al. 1989; Thiele et al.
2000). Such elements typically target cytokine mRNAs for destabilisation; however, the AUUUA motifs present in TCTP mRNA do not comprise the complete
consensus sequence for such destabilisation elements. To my knowledge, there is
currently only limited experimental evidence for regulated degradation of TCTP
mRNA. In contrast, the aforementioned high degree of structure formation
(Bommer et al. 2002) would indicate that it is a rather stable mRNA molecule,
consistent with the early observation that a large proportion of the mRNA exits in
untranslated mRNP particles (Yenofsky et al. 1982).
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Molecular Structure, Conservation and Interactions

As mentioned above, elucidation of the amino acid sequence of TCTP did not
reveal anything about the functional implication of the protein. Only the first
publication of the solution structure of TCTP from the fission yeast (Thaw et al.
2001) provided some structure-derived information about a possible functional
association of the protein. It revealed similarity to the Mss4/Dss4 family of
proteins, a group also called guanine nucleotide-free chaperones.
The amino acid sequences of TCTP are highly conserved throughout all eukaryotic taxa; several sequence comparisons have been published recently (Yubero et al.
2009; Hinojosa-Moya et al. 2008; Thayanithy 2005), and a detailed phylogenetic
analysis using 93 different TCTP sequences revealed that, by and large the phylogeny of TCTP sequences is consistent with the evolutionary history, although
there were some exceptions (Hinojosa-Moya et al. 2008).
The three-dimensional structures of the following TCTP proteins were solved
and are deposited in the databases: The solution structures of fission yeast (Thaw
et al. 2001) and human TCTP (Feng et al. 2007a), as well as the crystal structures of
Plasmodium knowlesi (Vedadi et al. 2007) and human TCTP (Susini et al. 2008) at
2 Å resolution. A mutant version of human TCTP showing a structure very similar
to the normal protein (Dong et al. 2009) can be found as well. Figure 4.1 shows the
solution structure of human TCTP as an example, since in the crystal structure, the
flexible loop domain is not displayed. The figure demonstrates the three major
domains of the TCTP protein.

flexible loop
α-helical
domain

β-stranded
core domain
N
C

Fig. 4.1 NMR structure of human TCTP. Secondary structure elements are highlighted as
follows: magenta: α-helices, yellow: β-sheets, blue lines: unstructured areas; major domains are
indicated (from: Feng et al. 2007a, PDB ID: 2HR9)
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A considerable number of 3D structures of other members of the TCTP family,
in particular from various plant species, have been predicted (Gutierrez-Galeano
et al. 2014; Hinojosa-Moya et al. 2008; Berkowitz et al. 2008), based on the
experimentally determined 3D-structures of TCTP and on sequence comparisons.
Phylogenetic comparisons showed that the predicted tertiary structure of TCTP
proteins is in general highly conserved throughout evolution (Gutierrez-Galeano
et al. 2014; Hinojosa-Moya et al. 2008), although there are some deviations in the
TCTP structure of lower eukaryotes (Hinojosa-Moya et al. 2008) and some species
of chlorophyta do not seem to have a TCTP gene at all (Gutierrez-Galeano et al.
2014). In the plant kingdom, two principal types of TCTP structures are being
distinguished, with some plants having the gene for one of the two types, whereas
other ones have genes for both types (Gutierrez-Galeano et al. 2014).
Since TCTP is involved in a wide range of biological processes, it is not
surprising that it undergoes interactions with a large number of partner proteins.
The distinct domain structure (Fig. 4.1) is likely to enable the protein to interact
with many other proteins (and with itself) in a specific manner. In 2012, Toshi
Kawakami published a review article summarising the TCTP/HRF interactions
known at the time (Kawakami et al. 2012). In the meantime, a considerable number
of additional interaction partners were identified, so it is timely now to compile an
updated list, as shown here in Table 4.1. This table provides an overview on the
many interaction partners and biological processes TCTP/fortilin/HRF is involved
in, some of which will be discussed in the following sections. Recent interaction
screens indicate that a much larger number of proteins have the potential to interact
with TCTP (see e.g. Li et al. 2016), however only a limited number of those have
actually been validated today.

4.2

Biological Functions of TCTP

4.2.1

Maintaining Cell Homoeostasis and Survival

4.2.1.1

Anti-apoptotic Activity: Discovery and Mechanisms

The anti-apoptotic activity of TCTP was originally discovered in Ken Fujise’s
laboratory, where the name ‘fortilin’ was coined (Li et al. 2001). Their study
described the cytoprotective effect of TCTP/fortilin overexpression against
etoposide-induced apoptosis in HeLa cells. Since then, the anti-apoptotic activity of
TCTP has been reported on numerous occasions and in a range of different settings,
which will be discussed below. Major support for the cytoprotective role of TCTP
came from gene-knockout studies in mice, which demonstrated that TCTP-knockout
was embryonic lethal, due to excessive apoptosis at an early embryonic state (Susini
et al. 2008; Chen et al. 2007a; Koide et al. 2009). The following mechanisms have
been proposed to underlie the anti-apoptotic activity of TCTP/fortilin:

Survival, apoptosis
prevention

Biological function
Stress response

Hong and Choi (2016)
Li et al. (2016)

Protection from ROS
DNA damage response (DDR)
Genome stability
Stress response,
DNA damage response (DDR)
Heat shock protection
Proteasome inhibition
Ubiquitinylation of VHL,
stabilisation of HIF-1α
Degradation of p53

Stabilisation of Mcl-1/TCTP
T-cell survival

N-terminus
α-Helical domain

α-Helical domain

Mcl-1

Bcl-XL

Apaf-1
Hsp27
Mitochondria

Chemoresistance
Stabilisation of TCTP
Apoptosis prevention

Degradation of p53

α-Helical domain

Stress granules
Ubp3, Cdc48 in yeast
VHL Tumour
suppressor
p53

MDM2/HDM2

N-terminus

Amson et al. (2012), Chen et al.
(2011), Rho et al. (2011)
Amson et al. (2012),
Funston et al. (2012)
Liu et al. (2005), Roque et al. (2016),
Zhang et al. (2002)
Yang et al. (2005),
Thebault et al. (2016)
Jung et al. (2014)
Baylot et al. (2012)
Rinnerthaler et al. (2006),
Susini et al. (2008)

Rinnerthaler et al. (2013)
Rinnerthaler et al. (2013)
Chen et al. (2013a)

Chattopadhyay et al. (2016)
Zhang et al. (2012)

Ca2+-related processes

α-Helical domain

N- and C- terminus

References
Jung et al. (2004), Kim et al. (2008a)
Yoon et al. (2006)
Feng et al. (2007a), Graidist et al.
(2007), Kim et al. (2000)
Rid et al. (2010)

Biological importance
Na-K-ATPase inhibition
Na-K-ATPase activation
Ca2+-scavenging

Binding site in TCTPa
C-terminus

Vitamin-D3
receptor
Peroxiredoxin-1
ATM kinase and
γH2A.X
Brahma
Y-box binding protein 1

Binding partner
Na-K-ATPase
Sorting nexin 6 (SNX6)
Ca2+

Table 4.1 TCTP interaction partners
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40S ribosomal subunit
Rheb GTPase
14-3-3 proteins
TSAP6
TCTP
Specific antibodies
Haemin
TCTP-dimer
His76/His77

Core domain
(TCTP and Rheb)

α-Helical domain and
core domain

TCTP dimerisation

Cell cycle progression
Stabilisation of Pim-3
Cdc25C degradation
Organ development
ES cell proliferation
ES cell proliferation
ES cell maintenance
Regulation of autophagy
Stabilisation of eEF1A-GDP
Inhibition of the GEF activity
of eEF1Bβ
Ribosome binding in yeast
Drosophila, TOR activation
Drosophila, organ growth
TCTP export in exosomes
Dimerisation

Flexible loop
N-terminus

Plk-1 kinase
Pim-3 kinase
Cdc25C phosphatase
ATM kinase
Nucleophosmin
Nucleolin
Oct-4
ATG16
eEF1A
eEF1Bβ

Microtubule stabilisation
Spindle stabilisation
Located at spindle

α-Helical domain
α-Helical domain

Mitot./meiotic spindle
Chfr
(checkpoint protein)
Actin filaments

α- and β-tubulin
Microtubules

Where determined, the location of the binding site in the respective TCTP domain (Fig. 4.1) is indicated

a

Extracellular function and
allergic response

Protein synthesis; growth
regulation

Early development

Cytoskeleton, cell cycle/
division

Bazile et al. (2009),
Tsarova et al. (2011)
Yarm (2002), Cucchi et al. (2010)
Zhang et al. (2013)
Chan et al. (2012b)
Hong and Choi (2013)
Johansson et al. (2010a)
Johansson et al. (2010b)
Johansson and Simonsson (2010)
Chen et al. (2014a)
Cans et al. (2003)
Cans et al. (2003), Langdon et al.
(2004), Wu et al. (2015)
Fleischer et al. (2006)
Dong et al. (2009), Hsu et al. (2007)
Le et al. (2016)
Amzallag et al. (2004)
Kim et al. (2009a), Lucas et al. (2014)
Kashiwakura et al. (2012)
Lucas et al. (2014)

Gachet et al. (1999)
Gachet et al. (1999),
Jaglarz et al. (2012)
Gachet et al. (1999), Jeon et al. (2016)
Burgess et al. (2008)
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1. Cooperation with other anti-apoptotic proteins. Two anti-apoptotic proteins of
the Bcl-2 family have been shown to interact with TCTP, i.e. Mcl-1 (Liu et al.
2005; Zhang et al. 2002) and Bcl-XL (Yang et al. 2005). In the case of Mcl-1, it
was reported that TCTP stabilises Mcl-1 (Liu et al. 2005) and vice versa (Zhang
et al. 2002), but another study also showed that both proteins are able to exert
their anti-apoptotic activity independently of each other (Graidist et al. 2004).
Recently, the interaction of TCTP with Bcl-XL was investigated in more detail
(Thebault et al. 2016). This study demonstrated that TCTP has a BH3-like
domain. Binding to such BH3 domains (Bcl2 homology domain 3) typically
inhibits anti-apoptotic proteins; however, TCTP’s BH3-like domain actually
activates the anti-apoptotic activity of Bcl-XL (Thebault et al. 2016). Thus, in
both cases, Mcl-1 and Bcl-XL, interaction with TCTP stimulates or maintains
their activity.
2. Preventing apoptotic mechanisms. The pro-apoptotic protein Bax promotes the
execution of apoptosis by inserting itself via an α-helical domain into the mitochondrial membrane, forming a homo- or heterodimer (with Bak) and inducing
membrane permeability and cytochrome c release. A detailed study by the
Telerman-group demonstrated that the α-helical domain of TCTP (Fig. 4.1) resembles that domain of Bax, which is crucial for its activity (Susini et al. 2008). They
also showed that TCTP, with its α-helical domain, is able to insert itself into the
mitochondrial membrane and to prevent the dimerisation and activation of Bax.
Translocation of TCTP (Mml1) to the mitochondrial surface was also observed in
yeast after mild oxidative stress (Rinnerthaler et al. 2006). Another apoptotic
mechanism affected by TCTP is the formation of the apoptosome. A core component of this structure is the apoptotic protease activating factor (Apaf-1), whose
inactivation has been implicated in carcinogenesis and the development of anticancer drug resistance (Fadeel et al. 2008). A recent report by the group of
Kyunglim Lee documented that TCTP binds to Apaf-1 via its caspase recruitment
domain and inhibits the activation of caspase 9 (Jung et al. 2014).
3. Antagonism to p53. The tumour suppressor protein p53 is a very powerful
pro-apoptotic agent, so interfering with its activity is an essential strategy for
anti-apoptotic players. Conversely, down-regulation of anti-apoptotic proteins
forms part of the armory of p53 to promote apoptosis. Indeed down-regulation of
TCTP through activation of a (temperature-sensitive) mutant protein of p53
(Tuynder et al. 2002; Bommer et al. 2010) was an initial observation in this
context. The mutual antagonism between p53 and TCTP was then described by
three groups in brief succession (Amson et al. 2012; Chen et al. 2011; Rho et al.
2011). The underlying mechanisms involved in this included the following:
(1) TCTP stimulates degradation of p53 (Rho et al. 2011) by binding to
P53-MDM2 complexes [or to HDM2 (Funston et al. 2012)] and promoting
MDM2-mediated ubiquitination and degradation of P53 (Amson et al. 2012).
(2) P53 as a transcription factor binds to a P53 responsive element in the
promoter region of the TPT1 gene and inhibits its transcription (Amson et al.
2012) [although p53-dependent induction of TPT1 transcription by has also been
reported (Chen et al. 2013b)]. (3) TCTP levels are also translationally regulated
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through the PI3-kinase/Akt/mTORC1 signalling pathway (Bommer et al. 2015).
Since this pathway is targeted by p53, through induction of its negative effectors
PTEN and TSC2 (Feng et al. 2007b), this implies that p53 also interferes with
TCTP synthesis at the translational level.
4.2.1.2

Involvement in Cellular Stress Responses

The cytoprotective action of TCTP has been demonstrated in a variety of cellular
stress responses, such as heat shock, oxidative, genotoxic or Ca2+-stress and in a
range of different cell lines. These effects of TCTP also contribute to its involvement in the development of drug resistance, a frequent problem in chemotherapeutic treatment of cancer.
1. TCTP and heat shock. Work on TCTP proteins from parasitic organisms
(Trichinella and Filarials) showed that TCTP behaves as a heat-shock protein
with chaperone-like activity. Its synthesis is induced after heat-shock treatment
(Gnanasekar et al. 2009; Mak et al. 2007). Both human and filiarial TCTP (from
Schistosoma mansoni) bind to denatured and native proteins, protecting the latter
from thermal denaturation (Gnanasekar et al. 2009). The yeast homologue of
TCTP, Mml1, has been shown to associate with stress granules in heat-shocked
cells and to modulate proteasome activity (Rinnerthaler et al. 2013).
2. TCTP in oxidative stress. Another filarial TCTP protein (from Brugia malayi)
was reported to display anti-oxidant activity. The reduced form of BmTCTP was
able to protect DNA from oxidative damage (Gnanasekar and Ramaswamy
2007). Similarly, TCTP prevented hydrogen peroxide-induced cell death in
murine fibroblasts (Nagano-Ito et al. 2009). Lucibello et al. studied the behaviour and role of TCTP in a panel of cancer cell lines under oxidative stress
conditions. They observed that TCTP is up-regulated in these cells under mild
oxidative stress, whereas strong oxidative stress resulted in reduced TCTP levels
and subsequent apoptotic cell death. Increased TCTP levels partially protected
cells from oxidation-induced cell death (Lucibello et al. 2011). Similarly,
overexpression of TCTP (TMA19) in yeast conferred resistance to arsenite to
the cells (Takahashi et al. 2010). A mechanism, by which TCTP (fortilin) could
exert this protective effect against ROS-induced cell death, was recently proposed by the Fujise laboratory (Chattopadhyay et al. 2016). They reported that
TCTP protects the enzyme peroxiredoxin-1 from degradation and keeps it in an
active state by blocking its deactivating phosphorylation by the protein
kinase Mst1.
3. TCTP, genotoxic stress and genome stability. The participation of TCTP in the
sensing and repair of DNA damage was first demonstrated by Zhang and colleagues in 2012 (Zhang et al. 2012). This involved the up-regulation of TCTP
after γ-irradiation of cells, its complex formation with the ataxia-telangiectasia
mutated (ATM) kinase and with the histone γH2A.X and colocalisation with
other DNA-damage marker proteins. Lack of TCTP resulted in severe deficiency
in chromosome damage repair. A more recent report on the interaction of
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Drosophila TCTP confirmed the (genetic) interaction with the ATM kinase and
its activation by TCTP (Hong and Choi 2013). These studies demonstrated the
importance of TCTP in maintaining genome stability under genotoxic stress,
which is consistent with observations from Fujise’s and our own laboratory,
showing that TCTP is able to protect cancer cells against the cytotoxicity exerted
by DNA-damaging anticancer drugs (Graidist et al. 2004; Bommer et al. 2017).
The involvement of TCTP in the development of chemoresistance in cancer
chemotherapy has also been emphasised by several other papers (Jung et al.
2014; Takahashi et al. 2010; He et al. 2015; Sinha et al. 2000).
4. Ca2+-stress and maintenance of ion homeostasis. Possibly the earliest functional
association of the TCTP protein to be discovered was the Ca2+-binding activity
of a protein from Trypanosomes (Haghighat and Ruben 1992). Later, it was
shown that TCTP levels are regulated in response to perturbations of intracellular Ca2+-homeostasis (Xu et al. 1999). Although TCTP does not have a canonical
Ca2+-binding site (Kim et al. 2000), its Ca2+-binding activity has been confirmed
by several laboratories using a range of methods (Feng et al. 2007a; Graidist
et al. 2007; Kim et al. 2000; Lucas et al. 2014; Arcuri et al. 2004, 2005; Sanchez
et al. 1997). However, the different approaches used to map the Ca2+-binding
site at the TCTP protein yielded different results (Feng et al. 2007a; Graidist
et al. 2007; Kim et al. 2000). Feng et al. demonstrated that it is a weak binding
site (Feng et al. 2007a); they provided the NMR structure of human TCTP
(Fig. 4.1) and mapped the Ca2+-binding site to a conserved part of the
β-stranded core domain, close to the ‘hinge’ region that connects it to the
α-helical domain. This result was consolidated and further refined in a very
recent study (Lucas et al. 2014). TCTP/fortilin has been reported to act as Ca2+scavenger, and this was proposed as a yet another mechanism of its antiapoptotic activity (Graidist et al. 2007). Indeed, overexpression of TCTP has
been shown to protect cells against Ca2+-dependent apoptosis induced by
thapsigargin (Graidist et al. 2007; Bommer et al. 2010), a reagent that inhibits
the Ca2+-pump of the ER membrane, resulting in a significant increase in
cytosolic Ca2+-levels. The notion of TCTP acting as a Ca2+- scavenger, or
more generally as a ‘buffer-like’ molecule for Ca2+, is consistent with its high
abundance and with the fact that its binding site is rather weak (Lucas et al.
2014). The importance of such a Ca2+-buffer-like function for TCTP was
described for trophoblast cells of the placenta, where it is involved in Ca2+handling and in its provision for the foetal blood circulation (Arcuri et al. 2005).
Similarly, in human prostate epithelial cells, TCTP is the Ca2+-binding protein
with the highest expression levels (Arcuri et al. 2004).
Another important player in maintaining intracellular ion homeostasis that is
influenced by TCTP is the membrane-bound Na+,K+-ATPase. Kyunglim Lee’s
group discovered that TCTP interacts with the third cytoplasmic domain of the
alpha subunit of the Na+,K+-ATPase in HeLa cells and inhibits its activity (Jung
et al. 2004). They also identified another protein, sorting nexin 6 (SNX6), that
binds to TCTP and neutralises TCTP’s negative effector activity on the Na+,K+ATPase, but does not have an inhibitory activity towards the enzyme on its own
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(Yoon et al. 2006). Since the Na+,K+-ATPase has been implicated in the
pathogenesis of hypertension, the group went on to employ a transgenic mouse
model that overexpresses TCTP. They showed that these mice developed systemic arterial hypertension about 6 weeks after birth, due to reduced Na+,K+ATPase activity and increased intracellular calcium (Kim et al. 2008a).
5. Other stress conditions. Regulation of TCTP levels in response to various stress
situations in plants has been studied recently. Protection against high or low
temperatures, salt stress or flooding are particularly important for plant survival,
and TCTP is regulated under all these conditions. For example, a recent study on
maize leaves subjected to flooding stress, reported that TCTP was increased in
response to flooding stress, possibly mediated by increased production of hydrogen peroxide (Chen et al. 2014b). TCTP from the rubber tree (Hevea
brasiliensis) was found to be regulated by drought, low temperature, high salt,
ethylene, hydrogen peroxide or wounding (Deng et al. 2016; Li et al. 2013). This
is consistent with the observation that overexpression of TCTP in Arabidopsis
resulted in increased drought tolerance of the plants (Kim et al. 2012a). Moreover, in the cabbage (Brassica oleracea), TCTP was found to be involved in
maintaining tolerance to heat, cold and to salt stresses (Cao et al. 2010). A study
on TCTP from cassava (Manihot esculenta Crantz) reported that the promoter
region of the TCTP gene harbours regulatory elements responsive to sodium
chloride and to pathogen infection, and that expression of this gene in bacteria
conferred a protective effect against salt stress (Santa Brigida et al. 2014). Two
other types of phytotoxic stresses, where TCTP appears to have a protective role,
is the stress induced by an excess of aluminium in slightly acidic soil (Ermolayev
et al. 2003) and the effect of mercury, as investigated in rice (Wang et al. 2012).
These findings relate to one of the earliest observations, which reported an
up-regulation of TCTP levels in cellular stresses. This study investigated the
effect of heavy metal-contaminated soils from mining areas on earthworms and
found that the presence of copper or cadmium in these soils led to an extreme
up-regulation of TCTP levels in these animals (Sturzenbaum et al. 1998).
Subsequently in mammalian cells, a metal-responsive element was discovered
in the TPT1 promoter that is highly responsive to copper (Schmidt et al. 2007),
confirming that this regulation occurs largely at the transcriptional level.

4.2.2

Involvement in the Cell Cycle and in Early
Development

4.2.2.1

TCTP, a Microtubule Stabilising Protein at the Mitotic
and the Meiotic Spindle

The property of TCTP/P23 as a tubulin-binding protein that associates with microtubules in a cell cycle-dependent manner was discovered in our laboratory in the
1990s (Gachet et al. 1999). Using deletion mutations, we characterised the tubulin-
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binding domain of TCTP as the part of the molecule, which was later identified as
the α-helical domain (Fig. 4.1; Thaw et al. 2001). This domain is characterised by a
rather basic charge, compared to the overall very acidic charge of the protein; 58%
of all basic amino acids are located in this domain, which also shows similarity to
the tubulin-binding domain of the canonical microtubule-associated protein
MAP-1B (Gachet et al. 1999). Furthermore, we established that overexpression of
TCTP/P23 results in microtubule stabilisation, and we showed that the protein
binds to the mitotic spindle, but is detached from the spindle during metaphaseanaphase transition (Gachet et al. 1999). Not shown in this paper are our results on
mitotic phosphorylation of TCTP/P23 (Fig. 4.2). In this experiment, we tested the
TCTP phosphorylating activity in cell extracts from synchronised HeLa cells at
different time points after release from the S-Phase block (Fig. 4.2a). The isoform
pattern of TCTP in these cells was analysed by 2D electrophoresis in the lab of
Jean-Charles Sanchez, Geneva (Fig. 4.2b). These results demonstrated that TCTP
phosphorylating activity is low throughout the cell cycle, but peaks sharply (nearly
ten-fold) in mitosis, which is consistent with a brief occurrence of an additional
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Fig. 4.2 TCTP is phosphorylated by a mitotic protein kinase activity. HeLa cells were
synchronised by an S-phase block using aphidicoline. Cell extracts were prepared at the indicated
time points after release from the block. The cell cycle phases indicated at the top of the graph
were verified by FACS-scan analysis (not shown). (a) Cell extracts were tested for TCTP kinase
activity by incubating of cell extracts (30 μg total protein) with 1 μg of GST–TCTP fusion protein
in the presence of 5 μCi [γ-32P]ATP in 50 mM MOPS buffer, pH 7.2, containing 1 mM DTT, 5 mM
MgCl2 and 5 mM p-NPP. The GST–TCTP fusion protein was recovered from the mixture on
glutathione-agarose beads and analysed for 32P incorporation by SDS electrophoresis, which was
quantified using a phosphoimager. The assay conditions were optimised before, and the incorporation was shown to be specific for TCTP. (b) Cells were harvested at the indicated time points
after release from the aphidicoline block and analysed by 2D-electrophoresis for TCTP isoforms
(Y. Gachet, M. Lee, I. Demalte, J.C. Sanchez and U.A. Bommer, unpublished results)

4 Biological Functions and Regulation of TCTP. . .

83

isoform of TCTP/P23 at the same time (Fig. 4.2b). The protein kinase that catalyses
the mitotic phosphorylation of TCTP was subsequently characterised by Frederic
Yarm as the mitotic master kinase Plk-1 (Yarm 2002). He also identified the
phosphorylation sites for Plk-1 as the serine residues 46 and 64 in the flexible
loop of the TCTP protein. Expression of a mutant protein bearing serine to alanine
mutations in these sites resulted in a dramatic increase in the number of
multinucleated cells, indicating that Plk-1-dependent phosphorylation of TCTP is
mediating the detachment of TCTP from the spindle, which in turn is essential for
the orderly progression through mitosis. In later studies, TCTP phosphorylation has
even been exploited as a marker for Plk-1 activity (Cucchi et al. 2010) and as a
potential prognostic marker in testing the efficacy of anticancer drugs (Lucibello
et al. 2015).
Localisation of TCTP to the mitotic spindle, particularly the spindle poles, was
also reported by other laboratories (Jaglarz et al. 2012; Burgess et al. 2008; Bazile
et al. 2009). A very recent paper even demonstrated the importance of TCTP for the
meiotic spindle in mouse oocytes (Jeon et al. 2016). These authors found that TCTP
is predominantly bound to the spindle poles and contributes to the stability of pole
microtubules, but not of kinetochore microtubules. TCTP is phosphorylated during
meiosis [as also in seen in bovine oocytes (Tani et al. 2007)], and overexpression of
a non-phosphorylatable mutant of TCTP led to disturbances of meiotic maturation
(Jeon et al. 2016).
A detailed study on plant (Arabidopsis thaliana; At) TCTP established that the
protein acts as mitotic growth integrator in both plants and animals by controlling
the duration of the cell cycle. In this function, the Arabidopsis and Drosophila
proteins are exchangeable in their respective systems (Brioudes et al. 2010). The
microtubule-binding activity of AtTCTP has been investigated in yet another paper
(Kim et al. 2012a); the binding to actin filaments (Bazile et al. 2009) and identification of an actin-binding site (Tsarova et al. 2011) were also reported for TCTP.
The importance of TCTP in cell cycle progression has been specifically studied
in cancer cells. For example, TCTP promoted cell cycle progression in pancreatic
cancer cells through stabilisation of the protein kinase Pim-3 (Zhang et al. 2013). In
hepatocellular carcinoma (HCC), the oncogene CHD1L was found to drive the
overexpression of TCTP, resulting in an increased number of mitotic defects (Chan
et al. 2012b). TCTP in turn promoted the degradation of Cdc25C during mitosis,
leading to a faster mitotic exit and miss-segregation of chromosomes and consequently to chromosomal instability.

4.2.2.2

Roles for TCTP in Early Development

1. TCTP in the reproductive system. The first reports on the role for TCTP in the
mammalian reproductive system appeared about 15 years ago. Specifically, the
developmental expression of TCTP in the rat and human testes were studied by
the group of Sanchez and Hochstrasser in Geneva (Guillaume et al. 2001), and
the importance of TCTP as a Ca2+-binding protein in the prostate (Arcuri et al.
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2004) and the placenta (Arcuri et al. 2005) were demonstrated by Arcuri et al. A
more recent study showed that TCTP is essential for the implantation of embryos
in the uterus of mice (Li et al. 2011). An important role for TCTP in egg
production in nematodes, such as C. elegans, was demonstrated by TCTP
knock-down, which severely reduced the number of eggs produced by these
worms (Meyvis et al. 2009), consistent with the role of TCTP for meiotic
maturation demonstrated in mouse oocytes (Jeon et al. 2016).
2. TCTP in early development. The most impressive evidence for the importance of
TCTP in early development was provided by TPT1-gene-knockouts in mice,
which resulted in embryonic lethality (Susini et al. 2008; Chen et al. 2007a;
Koide et al. 2009). The explanation typically given for this effect was ‘excessive
apoptosis at an early embryonic state’ (Susini et al. 2008; Chen et al. 2007a),
whereas another report reasons that the lack of TCTP results in an overactivity of
the BMP4 (bone morphogenetic protein 4) pathway, which is normally inhibited
by TCTP (Koide et al. 2009). The authors of this paper also show that in
Xenopus embryos TCTP/fortilin is particularly important for the formation of
neural tissue, even in the brain. This is consistent with a very recent report
showing that TCTP regulates axon development in the embryonic visual system
(Roque et al. 2016).
The importance of TCTP in early development was also demonstrated in
Drosophila, where TCTP-knockdown experiments established a role for TCTP
in the regulation of cell size and number, organ growth (Hsu et al. 2007) and
development (Hong and Choi 2013). Interaction partners of TCTP in this context
are the small GTPase Rheb, an upstream regulator of mTOR (mechanistic target
of rapamycin), and 14-3-3 proteins (Le et al. 2016). Knockout of TCTP in plants
(Arabidopsis thaliana) resulted in a male gametophytic phenotype with impaired
pollen tube growth. Moreover, TCTP knock-down resulted in severe developmental aberrations, such as slow vegetative growth, reduced leaf expansion and
lateral root formation and impaired root hair development (Berkowitz et al.
2008). A recent paper reports on the importance of TCTP (Rp41) for the
nodulation and root hair formation in Robinia pseudoacacia as another example
of TCTP’s involvement in plant developmental processes (Chou et al. 2016).
3. TCTP and pluripotency in somatic cell nuclei and ES cells. In 2007, several
papers documented the involvement of TCTP in early development and the
establishment of pluripotency after transplantation of somatic nuclei. Chen
et al. monitored the expression of TCTP in the eggs of the cephalochordate
Amphioxus after fertilisation and found that it is expressed in zygotes and the
early, but not the late, cleavage stages (Chen et al. 2007b). Koziol and colleagues
reported that TCTP, the gene product of Tpt1, acts as a transcription factor that
activates the transcription of oct4 and nanog in transplanted somatic nuclei
(Koziol et al. 2007). Oct4 and nanog are transcription factors that are critical
for reprogramming of somatic nuclei, when transplanted into oocytes or eggs.
Tani et al. observed that phosphorylated TCTP facilitates the first step of somatic
cell reprogramming in bovine oocytes (Tani et al. 2007), complementing the
study by Koziol. In contrast, another paper reported 5 years later that TCTP
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inhibited the Oct4 transcription and also decreased the pluripotency of murine
embryonic stem cells (Cheng et al. 2012). In 2010, Johansson and colleagues
investigated the interactions of TCTP/tpt1 in mouse embryonic stem cells
(ES cells) in more detail. They reported that TCTP interacts with the nucleolar
protein nucleolin (Ncl) (Johansson et al. 2010b) and with nucleophosmin
(Npm1) (Johansson et al. 2010a), and both these interactions peaked at mitosis,
but are independent of TCTP phosphorylation by Plk1. In a third paper, the
group also documents the direct interaction of both nucleoplasmin and TCTP
with Oct4, independently of each other (Johansson and Simonsson 2010). From
these interactions in ES cells, the authors deduce that TCTP has a role in ES cell
proliferation and maintenance (Table 4.1).

4.2.3

TCTP in Cell Growth Regulation, Protein Synthesis
and Degradation

4.2.3.1

TCTP and Cell Growth Regulation

One of the earliest observations on TCTP is the translational induction of its
synthesis upon growth stimulation of mammalian cells (Thomas et al. 1981; Bohm
et al. 1989, 1991; Thomas and Thomas 1986). Typically, we observed a four-fold
increase of TCTP levels after serum-stimulation of mammalian cells (Bommer et al.
2002, 2015). The involvement of TCTP in cellular growth regulation is documented
in various settings. One example, already mentioned above, described the role for
TCTP in the regulation of cell size and number, as well as organ growth (Hsu et al.
2007) and development (Hong and Choi 2013) in Drosophila. In plants, it was
shown that knockout of TCTP resulted in a phenotype with a slow vegetative growth
and impaired pollen tube growth (Berkowitz et al. 2008). Another recent paper
showed that in the Tobacco plant, TCTP is able to interact with the ethylene receptor
histidine kinase-1 and to enhance plant growth through promotion of cell proliferation (Tao et al. 2015).
The regenerating rat liver was frequently used as an experimental model for
studying processes of cell growth regulation in rodents. In 2008, Zhu et al. observed
that in rat liver, TCTP mRNA levels are transiently up-regulated in the time period
up to 12 h after partial hepatectomy, which indicates that the protein is required for
tissue growth during liver regeneration (Zhu et al. 2008). This is consistent with a
recent report showing that both the expression of intracellular TCTP and the release
of TCTP protein into serum were significantly increased in rats after partial
hepatectomy, and that enhanced TCTP levels promoted hepatocyte proliferation
(Hao et al. 2016).
The influence of TCTP on cellular signalling processes that are involved in the
regulation of growth and survival was studied by the group of Kyunglim Lee. They
reported that overexpression of TCTP in HeLa cells resulted in tyrosine phosphorylation of the epidermal growth factor receptor and in activation of both the Ras/Raf/

86

U.-A. Bommer

ERK and the PI3K/Akt pathways (Kim et al. 2009b). In a more recent paper, they
provided a link to the activity of TCTP in binding to and inhibiting the Na,KATPase, which they had observed earlier (Jung et al. 2004). The authors found
that TCTP in binding to the third cytoplasmic domain of the Na,K-ATPase results in
release and activation of the protein kinase Src and consequently in the activation of
the PI3K/Akt and the Ras/Raf/ERK pathways, as well as of additional signalling
pathways (Jung et al. 2011). A more recent paper from this group also described a
novel activity of (recombinant) TCTP in enhancing the neurotransmitter release
from the neurosecretory pheochromocytoma (PC12) cells (Seo et al. 2016).
The signalling pathway most intimately linked to cell growth regulation is the
PI3K/Akt-mTORC1 (mechanistic target of rapamycin complex 1) pathway. It is part
of a complex signalling network that regulates several anabolic processes, inclusive
of protein synthesis (Laplante and Sabatini 2012; Zoncu et al. 2011). In 2007, Hsu
et al. published a paper describing TCTP in Drosophila as a direct activator of this
pathway, acting as a guanine nucleotide exchange factor (GEF) for the small GTPase
Rheb, upstream of mTORC1 (Hsu et al. 2007). Consistent with this, reducing
Drosophila TCTP levels reduced cell size, cell number and organ size, similar to
Rheb mutant phenotypes. Subsequently, this group also reported that the 14-3-3
proteins regulate the interaction between TCTP and Rheb, thus playing an important
role in regulating organ growth in Drosophila (Le et al. 2016). The TCTP–Rheb
interaction was further confirmed for the human proteins by molecular modelling
studies (Dong et al. 2009). The first description of a NMR structure of TCTP had
revealed a similarity of TCTP to the MSS4/DSS4 proteins, which bind to the Rab
family of small GTPases (Thaw et al. 2001). Thus, the idea that TCTP acts as a GEF
for Rheb appeared attractive, but it remains controversial, since later studies failed to
support the results described for Drosophila: We found that reducing TCTP levels
did not reproducibly affect mTORC1 signalling in human cells, and we were unable
to detect a stable interaction between TCTP and Rheb (Wang et al. 2008). Similarly,
Rehmann and colleagues did not detect GEF activity of TCTP for Rheb or any
interaction between TCTP and Rheb (Rehmann et al. 2008).
Last but not least, the frequent reports on TCTP overexpression in cancer cells
and human tumours (reviewed in Bommer 2012; Acunzo et al. 2014; Chan et al.
2012a; Koziol and Gurdon 2012) and on its down-regulation in the tumour reversion model (Telerman and Amson 2009; Amson et al. 2013) provide additional
compelling evidence that TCTP is a growth-promoting protein. These aspects are
discussed below, in Sect. 4.3.1.

4.2.3.2

The Involvement of TCTP in Protein Synthesis

Cell and organ growth is dependent on the up-regulation of anabolic pathways, in
particular protein synthesis. The core regulatory hub for this regulation is the
mTORC1 pathway, which regulates protein synthesis through several mechanisms.
For example, mTORC1 enhances the proteosynthetic capacity of the cell through
stimulating ribosome synthesis, resulting in an increase in ribosome numbers. This is
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achieved through regulation of rRNA synthesis and the selective translational
activation of a subset of mRNAs, the ‘TOP-mRNAs’ whose joint feature is the
presence of the 50 -terminal-oligopyrimidine tract (50 -TOP). This group of mRNAs
largely comprises those mRNAs coding for components of the translational apparatus, in particular ribosomal proteins and translation factors (Meyuhas and Kahan
2015; Meyuhas 2000). The observations that the mRNA of TCTP also bears a
50 -TOP (Yamashita et al. 2008; Meyuhas 2000) and is regulated through the
mTORC1 pathway (Bommer et al. 2015) would suggest that TCTP also participates
in the activities (or regulation) of the translational machinery. In fact, as early as
2003, the Telerman group identified translation elongation factor eEF1A and its
guanine nucleotide exchange factor eEF1Bβ as TCTP-interacting partners (Cans
et al. 2003). TCTP stabilised the GDP form of eEF1A, and impaired the GDP
exchange reaction promoted by eEF1Bβ, thereby acting as an inhibitor of the GEF
function, in contrast to the activation of the GEF activity of TCTP for Rheb,
mentioned above. The interaction of TCTP with eEF1Bβ was later confirmed by
Langdon et al. (2004), and a more recent structural analysis of this interaction
demonstrated that it represents the most conserved interaction of TCTP, indicating
that this might be a primary function of the protein (Wu et al. 2015). A functional
screen of proteins associated with ribosomal complexes in yeast identified TCTP as
a translation-machinery-associated (TMA) protein, TMA19 (Fleischer et al. 2006).
Analysis of yeast mutant strains, deleted in TMA19, revealed that such strains have a
reduced rate of protein synthesis and alterations in polysome profiles, lending further
support to the notion that TCTP is involved in protein synthesis.

4.2.3.3

TCTP in the Regulation of Protein Degradation

There are a few instances, where TCTP was also reported to be involved in the
regulation of protein degradation. Typically, these were examples of degradation of
specific proteins or participation in autophagy, which either serve to accomplish
cell-cycle-dependent processes or otherwise to maintain cellular homeostasis. The
involvement of TCTP in the regulation of autophagy in mammalian cells and the
underlying mechanism was studied in a recent paper. The authors presented data
showing that TCTP interacts with the ATG16L1 complex, which is directly
engaged in the autophagy pathway (Chen et al. 2014a). They demonstrated that
TCTP positively regulates autophagy through the AMP-activated protein kinase
(AMPK) pathway, which also involves mTORC1. This is in contrast to a more
recent study, which showed that TCTP inhibits the process of autophagy (see ‘Note
Added in Proof’).
The same group investigated the interaction of TCTP with the tumour suppressor
protein ‘von Hippel–Lindau protein’ (VHL), which functions as an E3 ubiquitin
ligase and is involved the degradation of hypoxia-inducible factor HIF1. They
demonstrated that TCTP binds specifically to the VHL protein and promotes its
ubiquitinylation and subsequent degradation, in this way stabilising the HIF1 protein
(Chen et al. 2013a). Another important example of TCTP being involved in regulation of protein levels via modulation of protein degradation is the tumour
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suppressor protein p53. That TCTP overexpression promotes P53 degradation has
been demonstrated independently by three groups (Amson et al. 2012; Rho et al.
2011; Funston et al. 2012). It does this by binding to P53-MDM2-containing
complexes and inhibiting MDM2 auto-ubiquitination, thereby promoting MDM2mediated ubiquitination and degradation of P53 (Amson et al. 2012; Funston et al.
2012).
An interesting point is that TCTP was shown to stabilise the proto-oncogenic
protein kinase Pim-3, which is involved in promoting cell cycle progression and the
development of pancreatic cancer (Zhang et al. 2013). In this case, TCTP prevents
the degradation of Pim-3 via the ubiquitin–proteasome pathway. Yet another
example of a protein that is involved in cell-cycle regulation, and whose levels
are modulated by TCTP, is the cell-cycle-dependent phosphatase Cdc25C. The
ubiquitin–proteasome-dependent degradation of Cdc25C is an important step in
mitotic progression. It was shown that in hepatocellular cancer (HCC) this step is
promoted by overexpression of TCTP, leading to a faster mitotic exit and consequently to chromosome miss-segregation (Chan et al. 2012b). On the other hand,
TCTP itself has been found to be subject to proteasomal degradation after the first
embryonic mitosis in Xenopus laevis (Kubiak et al. 2008).
The involvement of TCTP with the proteasomal machinery in more general
terms has also been demonstrated in two other studies. Rinnerthaler and colleagues
showed that in yeast, under heat stress conditions, the TCTP homologue Mmi1
binds to components of the proteasomal complex and to cytoplasmic stress granules. These proteasomal components, to which TCTP colocalises, are typically
involved in protecting protein substrates from degradation (Rinnerthaler et al.
2013). Another proteomics study on colon cancer cells identified 27 proteins,
whose levels were altered after TCTP knockdown. In particular, components of
ubiquitin–proteasome system and proteins involved in the cytoskeleton were
affected under this condition (Ma et al. 2010).

4.2.4

Extracellular Functions of TCTP

4.2.4.1

TCTP as Extracellular ‘Signaling Molecule’ in Immune
Reactions

Since other chapters of this book will certainly consider the extracellular functions
of TCTP in more detail, this aspect of TCTP function will be covered only briefly at
this point. In 1995, Susan Macdonald’s group first described the presence of an
‘IgE-dependent histamine-releasing factor (HRF)’ in biological fluids of allergic
patients, which was also produced by lymphocytes of atopic children (MacDonald
et al. 1995). The molecular characterisation revealed that this protein is identical to
TCTP (or p21/p23). Since then, a plethora of papers was published relating to this
extracellular function of TCTP/HRF, which I will briefly summarise under the
following points. [For a more detailed account, the reader is referred to three recent
review articles on this matter (MacDonald 2012a, b; Maeng et al. 2012).]
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1. Release of local signalling molecules from immune cells, triggered by extracellular TCTP/HRF. The focus of the initial publication, which identified TCTP as
HRF, was on the IgE-dependent of histamine release in biological fluids from
allergic patients (MacDonald et al. 1995). However, a number of subsequent
studies revealed that the ‘scope’ of TCTP/HRF as an extracellular ‘signalling
molecule’ in immunological reactions is much wider, in that its activity is not
IgE-dependent and that it is able to modulate the release of various cytokines in
a number of different cell types involved in immune functions (MacDonald
2012a, b). These include B-cells (IL-1, IL-8 release), basophils (IL-4, IL-13
release), T-cells (inhibition of IL-2, IL-13 release), bronchial epithelial cells
(IL-8, GM-CSF release) and GM-CSF-primed eosinophils (IL-8 release) (Macdonald 2012b). The potential binding of TCTP to IgE antibodies was a matter
of debate (Wantke et al. 1999), but a more recent paper showed that the
dimerised form of TCTP is able to bind to a subset of IgE and IgG molecules
(Kashiwakura et al. 2012).
2. Intracellular signalling events induced by TCTP/HRF in immune cells. In order
to gain insight into the intracellular signalling pathways/events that are involved
in mediating the TCTP/HRF-dependent release of histamine and cytokines from
immune cells, the MacDonald group studied signalling events in basophiles that
were triggered by human recombinant TCTP/HRF for histamine release. They
found that the activity of the inositol 50 phosphatase SHIP-1, which inhibits the
PI3-kinase signalling pathway, is inversely correlated with the HRF-dependent
histamine release in basophils from IgE(+) donors. This finding was corroborated by the demonstration that the PI3-kinase inhibitor Ly294002 also
prevented the HRF-dependent histamine release in these cells (Vonakis et al.
2001). In another study, they showed that, in TCTP/HRF-responsive basophils
(but not in non-responsive ones), HRF-treatment resulted in phosphorylation of
the protein kinase Akt (Vonakis et al. 2008), further confirming that the
PI3-kinase pathway is involved in mediating the intracellular events in these
type of cells.
3. Secretion of TCTP, pathways and regulation. Secretion of TCTP was reported
from a number cell types, largely cells involved in the immune system, such as
macrophages, dendritic cells and PBMN cells, as well as a range of cancer cells
(reviewed in Maeng et al. 2012). This paper also names the different agents that
trigger and regulate TCTP release, and it describes the underlying mechanisms
for secretion in detail, which I will only briefly summarise here. First, the protein
TCTP does not have a signal sequence (Chitpatima et al. 1988; Gross et al.
1989), and no precursor protein for TCTP was detected, meaning that TCTP is
not secreted through the classical secretory pathway, via the ER and Golgi
apparatus. This was confirmed by the finding that its secretion was insensitive
to brefeldin A or monensin, two inhibitors of this pathway (Amzallag et al.
2004). These authors proposed a non-classical pathway for the secretion of
TCTP. They showed that TCTP interacts with TSAP6, a transmembrane protein,
which is induced by the tumour suppressor protein p53, and that TSAP6 and
TCTP co-localise to vesicular structures at the plasma membrane, indicating that
TCTP is secreted through an exosomal pathway, guided by TSAP6.
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Overexpression of TSAP6 did indeed result in increased TCTP levels in
exosome preparations and in enhanced secretion of TCTP (Amzallag et al.
2004), whereas cells derived from TSAP6-deficient mice are severely
compromised in the DNA damage-induced p53-dependent exosomal secretory
pathway (Lespagnol et al. 2008). Another, also exosome-related pathway for
TCTP secretion, was proposed by the Kyunglim Lee’s group. –They discovered
that TCTP secretion from HEK293 and U937 cells is inhibited by proton pump
inhibitors (PPIs), such as omeprazole and pantoprazole, which are inhibitors of
the human gastric H(+)/K(+)ATPase and are used in the treatment of gastric
ulcers (Choi et al. 2009). Consistent with this, overexpression of the ATPase
increased TCTP secretion from these cells, and the authors concluded that this
enzyme might facilitate the secretion of TCTP via a non-classical pathway.

4.2.4.2

TCTP Dimerisation and Other Extracellular Roles

The ability of TCTP to self-interact was discovered in Dr. Lee’s group as early as in
2000, using the yeast two-hybrid system and co-immunoprecipitation (Yoon et al.
2000). Later, the same group detected the dimerised protein in sera from allergic
patients, and they showed that dimerisation is essential for the cytokine-like
properties of TCTP/HRF. For dimerisation to happen, the protein had to undergo
an N-terminal truncation of about eleven amino acids (Kim et al. 2009a). The group
also identified a 7-mer peptide that was able to bind to dimerised TCTP and to
inhibit its cytokine-like activity in a cellular assay system and in a mouse model
(Kim et al. 2011). Based on their findings and on additional evidence, the authors
developed a hypothesis describing two potential mechanisms for the activation
(through dimerisation) of extracellular TCTP/HRF to acquire cytokine-like properties (Kim et al. 2013a): (1) A ‘spontaneous’ mechanism, involving extracellular
proteases that trigger N-terminal truncation of the protein and subsequent
dimerisation, driven by reactive oxygen species (ROS), which frequently occur in
inflammatory processes. (2) Dimerisation by binding to HRF-reactive IgE antibodies, which would confer autoantigen properties to HRF. In each case, only the
dimerised TCTP/HRF would bind to the target cell and trigger cytokine release.
These ideas are discussed in detail in their review article (Kim et al. 2013a).
Dimerisation of TCTP was reported by other groups in quite different contexts.
Gnanasekar et al. characterised the TCTP protein from filarial parasites and found
that it occurs in multimeric forms (Gnanasekar et al. 2002). Meshnick and co-workers
described TCTP from Plasmodium falciparum as a target protein for the antimalarial
drug artemisinin (Bhisutthibhan et al. 1999). They observed that dihydroartemisinin
may form adducts with both the monomeric and dimeric form of TCTP
(Bhisutthibhan and Meshnick 2001). A recent detailed study on ligand binding to
human TCTP revealed that binding of haemin to TCTP resulted in a conformational
change of the protein and promoted its dimerisation. In contrast, Ca2+-binding
resulted in destabilisation of TCTP dimers formed in the presence of haemin
(Lucas et al. 2014). The authors propose a ‘buffer-like’ function for TCTP, since it
is able to bind both haemin and Ca2+ at higher concentrations. For example, TCTP
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may be able to bind intracellular free haemin and keep it in a non-toxic state,
preventing the formation of ROS. This paper critically evaluates the earlier literature
on Ca2+-binding and on dimerisation of TCTP.
Extracellular ‘functions’ of TCTP were also described in the context of apoptosis. Apoptotic cell death includes a paracrine function, aimed at promoting tissue
repair in the vicinity of the dying cell. To this end, apoptotic cells release
nanovesicles containing a set of proteins, different from that of apoptotic blebs.
Sirois et al. studied such nanovesicles released from apoptotic endothelial cells and
identified TCTP as a prominent anti-apoptotic protein in these vesicles (Sirois et al.
2011). They went on to show that these nanovesicles induce an anti-apoptotic
phenotype in vascular smooth muscle cells (VSMCs), and that this activity is
abolished in nanovesicles treated with TCTP siRNA. Another, more recent paper
studied serum TCTP (fortilin) levels in mice and humans using a newly developed
ELISA. The authors found that TCTP/ fortilin levels are significantly elevated in
sera from patients with solid cancers, in response to chemo- or radiation therapy,
and concluded that TCTP is suitable as a biomarker for apoptosis in vivo
(Sinthujaroen et al. 2014).

4.3

Involvement of TCTP in Disease Processes

4.3.1

TCTP in Human Cancer

Other chapters in this book presumably deal with the ‘TCTP and Cancer’ topic in
more detail; I will here just summarise this important part of the TCTP story under
three subheadings.

4.3.1.1

Overexpression of TCTP in Human Tumours

As mentioned at the beginning, the name ‘translationally controlled tumour protein’
was derived from the fact that the cDNA for the first sequence of human TCTP,
published in 1989 (Gross et al. 1989), was obtained from a mammary carcinoma.
During the ensuing decade, some doubts were voiced on the term ‘tumour protein’,
since TCTP protein and mRNA were detected in essentially all eukaryotic cells and
tissues (Thiele et al. 2000; Hinojosa-Moya et al. 2008; Sanchez et al. 1997).
However, since the beginning of this century, a substantial body of evidence has
been accumulated, demonstrating that TCTP is indeed overexpressed in cancer
cells and in human tumours. A number of review articles have summarised these
efforts (Telerman and Amson 2009; Bommer 2012; Acunzo et al. 2014; Amson
et al. 2013; Chan et al. 2012a; Koziol and Gurdon 2012), and the reader is referred
to these for papers reporting overexpression of TCTP in cancer cell lines.
Table 4.2 provides a compilation of the types of human cancers, where
overexpression of TCTP was demonstrated in tumour tissues. The table lists only

Western blot
Immunohistochemistry
Immunohistochemistry

Proteomics methods

Oral cancer

Zhu et al. (2008)
Chan et al. (2012b)

RT-PCR (mRNA levels)
Immunohistochemistry

(Cell tumorigenicity)
Advanced tumours,
poor survival rate

Advanced tumours;
poor survival rate

Yagci et al. (2013)
He et al. (2015)

Immunohistochemistry
Immunohistochemistry

Lo et al. (2012)

Kim et al. (2008b)
Kobayashi et al. (2014)
Ramani et al. (2015)

Chung et al. (2000)
Friedman et al. (2004)
Slaby et al. (2009)
Bommer et al. (2017)
Xiao et al. (2016)

Deng et al. (2006)
Amson et al. (2012)

Gu et al. (2014)

Ambrosio et al. (2015)

References
Miao et al. (2013)

Clinical associations
High-grade gliomas,
poor survival rate
Immunohistochemistry, RT-PCR (mRNA levels) High-grade gliomas,
poor survival rate
Proteomics methods
Immunohistochemistry
Agressive tumours;
poor survival rate
Northern blot (mRNA)
Proteomics methods
Microarray analysis (mRNA)
Immunohistochemistry
(Cellular drug resistance)
Immunohistochemistry
High grades, metastases,
poor survival rate
RT-PCR, Western blot, Immunohistochemistry

Methods employed
Immunohistochemistry, Western blot

Kidney and Renal Cell Cancer
(RCC)
Leukaemia (CLL)
Lymphomas
(DLBCL, NHL, FL, NK/T-Cell)
Liver cancer
Hepatocellular carcinoma
(HCC)
Lung cancer
NF1-associated tumours
Neuroblastomas

Colorectal cancer

Breast cancer

Cancer type
Brain tumour: Gliomas

Table 4.2 TCTP overexpression in human cancers
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RT-PCR (mRNA levels)
Immunohistochemistry

Immunohistochemistry

Immunohistochemistry

Osteosarcoma
Ovarian cancer

Pancreatic cancer

Prostate cancer

(Cell tumorigenicity)
Poor prognosis,
Cisplatin resistance
High TCTP and Pim-3
in advanced tumours
Castration resistance
Baylot et al. (2012),
Kaarbo et al. (2013)

Zhang et al. (2013)

Shen et al. (2016)
Chen et al. (2015)

4 Biological Functions and Regulation of TCTP. . .
93

94

U.-A. Bommer

those papers, which have dealt specifically with one specific type of cancer. There
are two additional papers, where the authors have screened a range of cancers for
TCTP overexpression, compared to normal tissue, either by western blotting
(Tuynder et al. 2002) or using proteomics methods (Kuramitsu and Nakamura
2006). From this screening, it emerged that, apparently, TCTP was not
overexpressed in cancers of the stomach and the pancreas (Tuynder et al. 2002;
Kuramitsu and Nakamura 2006), of the oesophagus (Kuramitsu and Nakamura
2006) and the cervix (Tuynder et al. 2002), whereas overexpression was confirmed
for most other types of cancers investigated. However for pancreatic cancer, a later,
more specific study found high TCTP levels, particularly in advanced tumours
(Table 4.2). This example shows that for each type of cancer, we have to await more
detailed investigations, to confirm (or rule out) TCTP overexpression for a particular cancer type. Currently, the picture emerges that TCTP is overexpressed in a
large number of cancer types, certainly in the majority of those investigated so far.
Also, where clinical associations have been established, high TCTP levels were
typically associated with advanced tumours and poor patient outcomes (Table 4.2).

4.3.1.2

Mechanistic Involvement in Cancer Progression

The importance of TCTP in cancer was originally demonstrated through studies on
the ‘tumour reversion model’ in Adam Telerman’s group. This approach investigates
the rare events of tumour cells reverting back from the malignant to the normal
phenotype (Telerman and Amson 2009). The group showed that TCTP is one of the
important proteins, whose expression is down-regulated in this process. Knockdown
of TCTP resulted in suppression of the malignant phenotype (Tuynder et al. 2002)
and it led to a dramatically increased number of spontaneous revertants (Tuynder
et al. 2004). Another group used a proteomics approach to identify proteins that are
down-regulated in a reversion model of multiple myeloma. They identified STAT3
and TCTP, among other proteins, as being down-regulated in revertant cells
(Ge et al. 2011). The tumour reversion model was instrumental to demonstrate the
importance of TCTP in cancer, but the important question remained: What are the
mechanisms, through which this protein is able to promote cancer? The following
possibilities have emerged from the discussion in recent years.
1. Anti-apoptotic activity of TCTP. Overexpression of anti-apoptotic proteins is a
common feature and part of the survival strategy of cancer cells. It is therefore not
surprising that TCTP is often found to be overexpressed in cancer, alongside other
‘classical’ anti-apoptotic proteins, such as Bcl-2, Bcl-XL or Mcl-1. Since the
discovery of the anti-apoptotic activity of TCTP (fortilin) (Li et al. 2001), several
mechanistic aspects of this property have been reported (reviewed in Bommer
2012; Acunzo et al. 2014; Chan et al. 2012a). These were described earlier in Sect.
4.2.1 of this chapter and do not need to be outlined again. However, one of these
anti-apoptotic mechanisms ought to be mentioned here, i.e. the antagonism of
TCTP to the tumour suppressor protein p53, which is crucial for TCTP to exert its
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cancer-promoting activity (Amson et al. 2012; Chen et al. 2011). The
cytoprotective role of TCTP in cancer cells is well documented, for example in
conditions of oxidative stress (Lucibello et al. 2011), or of treatment with various
anticancer drugs, the latter often resulting in chemoresistance of these cells
(Li et al. 2001; Jung et al. 2014; Graidist et al. 2004; Bommer et al. 2017; He
et al. 2015), which is a frequent problem in cancer chemotherapy.
2. Promotion of mitosis. A very specific role of TCTP in cancer promotion was
described by Chan et al. in 2012, who studied the chromodomain helicase/
ATPase DNA-binding protein 1-like gene (CHD1L), which is a specific oncogene in human hepatocellular carcinoma (HCC) (Chan et al. 2012b). They found
that CHD1L acts as a transcriptional activator of TCTP and that the resulting
overexpression of TCTP contributed to the mitotic defects of tumour cells.
Moreover, TCTP promoted the ubiquitin–proteasome-dependent degradation
of the phosphatase Cdc25C during mitotic progression, resulting in a sudden
drop of Cdk1 activity in mitosis. The activity of the cyclin-dependent kinase
1 (Cdk1) is normally maintained by Cdc25C and is required for an orderly
mitotic exit. The sudden drop of Cdk1 activity caused by TCTP overexpression
resulted in a faster mitotic exit and chromosome miss-segregation, which in turn
led to chromosomal instability (Chan et al. 2012b). The observation that TCTP is
involved in regulating the degradation of Cdc25C through the ubiquitin–
proteasome pathway is consistent with other studies reporting a role of TCTP
in regulating the ubiquitin–proteasome-dependent degradation of specific
proteins (see Sect. 4.2.3). Further support comes from a proteomics study on
LoVo colon cancer cells reporting that TCTP knockdown results in the alteration
predominantly of components of the ubiquitin–proteasome system (Ma et al.
2010).
3. TCTP and growth signalling in cancer. There are several reports describing the
effects of alteration of cellular TCTP levels on growth signalling pathways.
These were covered earlier (Sect. 4.2.3). Briefly, TCTP overexpression was
found to activate the Ras/Raf/ERK, the PLC-γ and the PI3K/Akt growth signalling pathways in HeLa cells (Kim et al. 2009b). Also, Hsu et al. described TCTP
in Drosophila as an activator of the small GTPase Rheb, an upstream activator of
the mTORC1 pathway, and based on this, implicated TCTP in growth regulation
(Hsu et al. 2007). However, other follow-up studies could not confirm some of
the findings in mammalian cells (Wang et al. 2008; Rehmann et al. 2008). Thus,
while some studies indicate that TCTP could act as a growth-regulatory protein,
these ideas and the mechanisms involved need further consolidation.
4. TCTP in specific stages of cancer progression. Since TCTP is active in promoting
cellular growth and proliferation, one would expect the protein also to be
involved in the early stages of cancerous growth. Yet, there are not many
observations published on TCTP levels specifically in early cancer development.
Colorectal cancer (CRC) with its distinct morphology of precancerous lesions,
such as adenomas, is amenable for such investigations. Recently, we (Bommer
et al. 2017) and a Chinese group (Xiao et al. 2016) demonstrated that indeed
TCTP levels (assessed by immunohistochemistry) increase early in CRC, already
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at the adenoma stage. This is consistent with our finding that during growthinduction of both HeLa cells and HT29 colon cancer cells, TCTP synthesis is
translationally up-regulated through the PI3K/Akt/mTORC1 signalling pathway
(Bommer et al. 2015), given the earlier observation that this pathway is activated
early in the development of colorectal cancer (Zhang et al. 2009).
Epithelial-to-mesenchymal transition (EMT) of cancer cells is a crucial step
in the development of invasiveness and metastasis of tumours. In 2015, Bae et al.
published a paper showing that TCTP is able to promote EMT, cell migration
and invasiveness (Bae et al. 2015). They also used murine melanoma cells to
demonstrate that depletion of TCTP suppresses the development of pulmonary
metastasis in a mouse model. Several other studies also demonstrated a role for
TCTP in promoting cell migration and invasiveness of cancer cells, and the
formation of metastases in animal models. Examples are glioma cells (Jin et al.
2015) and a model for liver metastasis in SCID mice (Chan et al. 2012a);
however the cells most frequently studied in this context are those of colorectal
cancer. Knockdown of TCTP inhibited proliferation, migration and invasion
activities of LoVo colon cancer cells (Ma et al. 2010; Chu et al. 2011). Xiao and
co-workers reported that in colon cancer patients, TCTP expression levels were
higher in liver metastases, compared to primary tumours (Xiao et al. 2016). They
also showed that extracellular TCTP promoted migration and invasiveness of
CRC cells in vitro and contributed to distant liver metastasis in vivo. Another
example of TCTP being involved in advanced state malignant disease came
from a study on prostate cancer (PC). Baylot et al. demonstrated that TCTP is
particularly expressed in the castration-resistant form of PC and in metastases of
the bone, liver and lymph nodes resulting from this (Baylot et al. 2012). Their
results also show that knockdown of TCTP inhibits growth of prostate cancer
cells, progression of castration-resistant tumours in mice and reduces their
chemoresistance to docetaxel.
5. Anticancer drug resistance. A frequent problem in cancer chemotherapy is the
development of drug resistance, and some recent reports indicate that TCTP is
likely to be involved in this aspect of cancer as well. We have shown that HCT116
colon cancer cells respond to treatment with 5-fluorouracil (5-FU) or with
oxaliplatin, two agents frequently used in CRC treatment, with increased TCTP
expression. This is probably part of a cellular stress response, since increased
TCTP levels protected these cells against the cytotoxicity exerted by these drugs
(Bommer et al. 2017). Similarly, the contribution of TCTP (HRF) to the development of cell adhesion and chemoresistance was reported in non-Hodgkin
lymphomas (He et al. 2015). Lucibello et al. showed that in breast cancer cells,
inhibition of TCTP by dihydro-artemisinin resulted in increased sensitivity to
chemotherapy and that phospho-TCTP levels, an indicator of mitotic activity
(Yarm 2002), are particularly increased in breast tumours that are resistant
against treatment with the trastuzumab antibody (Lucibello et al. 2015).
Reports on the involvement of TCTP in anticancer drug resistance started to
appear as early as 2000. Sinha and co-workers performed a proteomics analysis
on human melanoma cell lines that were resistant to drugs like vindesine,
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cisplatin and etoposide. They identified TCTP as one of four proteins
overexpressed in those cell lines, compared to their no-resistant parental cells
(Sinha et al. 2000). Fujise’s laboratory demonstrated TCTP (fortilin)-dependent
drug resistance against etoposide (Li et al. 2001) and 5-FU (Graidist et al. 2004)
in U2OS cells. In a more recent study, Kyunglim Lee’s laboratory explored the
mechanism underlying the TCTP-dependent resistance against etoposide in
HeLa cells. They demonstrated that TCTP interacts with the apoptotic
protease-activating factor (Apaf-1), associates with the apoptosome and inhibits
activation of caspase 3 and execution of apoptosis (Jung et al. 2014).
4.3.1.3

TCTP as an Anticancer Target

Given the well-established role of TCTP in cancer as summarised in this section, it
is not surprising that the idea of exploring TCTP as an anticancer target protein is
not new, and this interesting topic has already been covered in six review articles
(Telerman and Amson 2009; Bommer 2012; Acunzo et al. 2014; Amson et al. 2013;
Efferth 2005, 2006). Here I will briefly summarise these efforts, according to the
groups of drugs investigated to target TCTP:
1. Artemisinin: Since the early discovery that TCTP of Plasmodium falciparum is a
target protein of the antimalarial drug artemisinin (Bhisutthibhan et al. 1998),
this drug interaction has been studied in more detail (Chae et al. 2006).
Artemisinin not only displays antimalarial activity but was also found to be a
potent anticancer agent in cellular assay (review in Efferth 2005), and screening
for potential targets in this context has confirmed that TCTP is indeed a target for
this drug (Efferth 2005, 2006). The interaction of artemisinin with TCTP was
then studied in cancer cells, and it was found that drug treatment results in
degradation of TCTP (fortilin) via the ubiquitin–proteasome pathway (Fujita
et al. 2008). More recent publications described proof-of-principle investigations for the use of artemisinin as an anticancer drug in cellular models of lung
cancer (Liu et al. 2014), of Neurofibromatosis type 1 (NF1)-associated tumours
(Kobayashi et al. 2014) and of breast cancer (Lucibello et al. 2015). Specifically,
the latter report demonstrated that dihydroartemisinin enhances the anticancer
effect of doxorubicin in triple-negative breast cancer cells and acts synergistically with the antibody Trastuzumab, which is used for the treatment of HER2/
neu positive breast cancers, to induce apoptosis of tumour cells.
2. Antihistaminics and antidepressants. Based on the identification of TCTP as
histamine-releasing factor HRF (MacDonald et al. 1995), the Telerman laboratory tested a panel of antihistaminic drugs for their effect on human leukaemia
and breast cancer cells (Tuynder et al. 2004). Of these ones, hydroxyzine and
promethazine displayed growth-inhibiting activity on these cells. These antihistaminics are structurally related to the antidepressants sertraline and thioridazine,
which also inhibited tumour growth, both in vitro and in vivo (Tuynder et al.
2004). All these drugs bind to TCTP and disrupt its interaction with other partner
proteins, eventually leading to increased release of the protein from the cell and to
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lowered intracellular TCTP levels (Telerman and Amson 2009). Since the demonstration of the reciprocal repressive feedback loop between TCTP and the
tumour suppressor P53 by the same laboratory (Amson et al. 2012), the mechanism of action of these drugs can be described in more detail as follows (Amson
et al. 2013): Binding of sertraline and thioridazine to TCTP prevents its binding to
MDM2 and consequently the destabilisation of P53. The resulting increased P53
levels lead to additional transcriptional inhibition of TCTP expression. An
additional mechanism is based on the finding that both sertraline (Lin et al.
2010) and thioridazine (Kang et al. 2012) inhibit the mTOR signalling pathway.
Blocking this pathway in itself will inhibit TCTP expression, since TCTP mRNA
translation is regulated through the mTOR pathway (Bommer et al. 2015). In
Drosophila, TCTP was described as a positive regulator of the mTOR pathway
via the small GTPase Rheb (Hsu et al. 2007); it is therefore possible that TCTP
and mTOR are in a positive feedback loop (Kobayashi et al. 2014), which would
be disrupted by treatment with sertraline or thioridazine. In a very recent paper,
two additional antihistaminic drugs, buclizine and levomepromazine, were
reported to inhibit cancer cell growth by binding to TCTP and by inducing cell
differentiation (Seo and Efferth 2016).
3. Antisense oligonucleotides (ASOs) and anti-TCTP peptide. Synthetic agents that
target TCTP were first used by Baylot and colleagues, who patented an ASO
against TCTP (Baylot et al. 2012). In their study, they used a mouse model to
show that treatment with the TCTP-ASO inhibits tumour growth in castrationresistant prostate cancer, enhances docetaxel chemotherapy and delays cancer
progression in vivo. This effect is associated with an increase in P53 levels
(Acunzo et al. 2014; Baylot et al. 2012). In addition, recently a peptide aptamer
(WGQWPYHC) targeting TCTP was tested and found to display specific cytotoxicity towards TCTP expressing tumour cells, without affecting normal cells
(Kadioglu and Efferth 2016).
In summary, both existing drugs that are in use for treatment of other disease
groups (antimalarials, antihistaminics, antidepressants) and synthetic agents
designed to specifically target TCTP show promising results in proof-of-concept
studies as potential approaches for anticancer treatment.

4.3.2

Participation in Immunological Reactions

Since the discovery of TCTP as an ‘IgE-dependent histamine-releasing factor
(HRF)’ in biological fluids of allergic patients (MacDonald et al. 1995), many
papers have been published, relating to the involvement of TCT/HRF in allergic
diseases and other activities of the immune system. The molecular and cellular
aspects of these extracellular activities of TCTP/HRF have been summarised in the
preceding Sect. 4.2.4. Here, I will just touch on some of the clinical aspects, based
on the reviews and some recent papers:
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As mentioned in Sect. 4.2.4, the extracellular function of TCTP/HRF consists of
a cytokine-like activity, in that it is able to trigger several types of immune cells to
release cytokines or other signalling molecules, not only the IgE-dependent histamine release from basophils, as described originally (reviewed in Macdonald
2012b; Kawakami et al. 2012). Although the association of TCTP/HRF with
human allergic disease has been widely accepted, its exact role in the clinical
context still awaits further clarification (Kawakami et al. 2012). Several smallgroup clinical investigations have established a correlation between the TCTP/HRF
status and a range of clinical parameters typical in allergic diseases. Such clinical
parameters include the following: (1) the sensitivity of basophils from a subpopulation of allergic donor patients to TCTP/HRF, (2) the intensity of symptoms in the
late phase reaction of the allergic response, (3) bronchial hyper-reactivity and
sensitivity to histamine, (4) the clinical status of food allergy and atopic dermatitis
(reviewed in Macdonald 2012b). However, not all clinical studies were able to
detect such correlations (see, e.g. Budde et al. 2002). The observation that the TCTP
proteins of two highly allergenic fungal species [Cladosporium herbarum (Rid
et al. 2008) and Alternaria alternata (Rid et al. 2009)] are able to cause histamine
release from human basophils and to compete with human HRF is also of interest in
this context.
Apart from establishing a clinical correlation, the next question is whether there
is indeed a causal relationship between HRF/TCTP levels (or activity) with the
disease symptoms. The generation of an inducible transgenic mouse model with
overexpressing HRF/TCTP targeted to lung epithelial cells was a first step to
address this question. These mice have increased HRF protein levels both in the
lung epithelium and extracellularly in the BAL fluid; moreover, HRF exacerbates
the allergic, asthmatic responses in these animals after ovalbumin challenge (Yeh
et al. 2010). An inherent problem for delineating the precise role of TCTP/HRF in
the allergic disease processes lies in its multifunctionality that entails many intracellular roles in addition to the extracellular ones, which makes it difficult to
exclude off-target effects (Kawakami et al. 2012).
There was some debate in the literature, whether or not TCTP/HRF binds
directly to IgE antibodies and in this way triggers histamine release from mast
cell and basophils (Kawakami et al. 2012). A recent detailed study demonstrated
that a subset of both IgE and IgG antibodies are able to bind TCTP/HRF
(Kashiwakura et al. 2012). Dimerisation of TCTP as a prerequisite for its
cytokine-like activity was shown before (Kim et al. 2009a, 2013a). Kawakami
and colleagues demonstrated in their paper that it is indeed dimerised TCTP/HRF
that binds to these antibodies. They mapped the binding site on TCTP and used
corresponding peptides to block its interaction with the ‘cognate’ IgE antibody.
They also showed that these Ig-interacting TCTP/HRF peptides inhibited IgE/HRFinduced mast cell activation in vitro and other allergenic symptoms in a mouse
model in vivo (Kashiwakura et al. 2012). This finding demonstrates that TCTP/
HRF has a proinflammatory role in asthma and skin hypersensitivity and also that it
can be considered a potential therapeutic target. This idea was not entirely new,
since just before, Dr. Lee’s group identified a 7-mer peptide that binds
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preferentially to dimerised TCTP and is able to block IL-8 release from BEAS-2B
cells triggered by dimeric TCTP. This peptide reduced eosinophil infiltration and
other symptoms in a mouse rhinitis model (Kim et al. 2011), and it is non-toxic
(Kim et al. 2013b). These two examples indicate that TCTP/HRF may indeed be a
valid target for the treatment of symptoms in allergic disease.

4.3.3

TCTP in Lower Animals and Parasitic Infections

There is a large number of reports on TCTP proteins and their biological function in
lower animals and plants. The high degree of conservation was mentioned in the
introduction (for review see Hinojosa-Moya et al. 2008). Here, I will focus on those
papers, which deal with the involvement of such TCTP proteins in infectious or
immune response processes or are otherwise potentially involved in human disease.

4.3.3.1

TCTP in Protozoans

The first TCTP protein described in a protozoan was from Plasmodium falciparum
(Pf), one of three parasites causing malaria. It was discovered as one of the target
proteins for the antimalarial drug artemisinin (Bhisutthibhan et al. 1998). This
paper demonstrated that TCTP reacts with artemisinin in situ and in vitro in the
presence of haemin and that it binds haemin itself. The interactions of Pf-TCTP
with artemisinin (Chae et al. 2006) and of human TCTP with haemin (Lucas et al.
2014) were subsequently studied in more detail, as was the subcellular location and
calcium-binding activity in Plasmodium (Bhisutthibhan et al. 1999).
The role of malarial TCTP in the host–parasite interaction was studied in three
papers: MacDonald et al. showed that malarial TCTP is secreted by the parasite and
can be detected in the blood of infected individuals (MacDonald et al. 2001). They
also showed that, like human TCTP/HRF, Pf-TCTP is able to stimulate histamine
release from basophils and IL-8 secretion from eosinophils, but is much less
efficient to do so. Thus, malarial TCTP could compete with human HRF for the
binding sites on the immune cells and in this way dim the host immune response.
Similarly, another paper demonstrated that Pf-TCTP is incorporated into mouse
splenic B-cells at a much higher rate than human TCTP, but has a much lower
proliferative effect on B-cells than its human counterpart (Calderon-Perez et al.
2014). A recent study even explored the potential of malarial TCTP as a vaccine to
reduce parasitaemia in mice. In two trials, a significant reduction in parasitaemia in
the early stages of infection was observed in BALB/c mice (Taylor et al. 2015).
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TCTP in Parasitic Worms

Reports on the biology of TCTP in parasitic worms typically revolve around the
topic of cyto-protection, defence and host–parasite interaction. Two papers characterise the calcium-binding properties of TCTP from the filarial parasites Brugia
malayi and Wuchereria bancrofti (Gnanasekar et al. 2002) and from Schistosoma
mansoni (Rao et al. 2002). They detected the parasite TCTP protein in the bloodstream of infected mice and described its histamine-releasing activity and the
promotion of allergic inflammatory responses associated with filarial infections in
these mice. The same group also characterised Brugia malayi TCTP as an antioxidant protein (Gnanasekar and Ramaswamy 2007) and TCTP from Schistosoma
mansoni as a heat-shock protein (Gnanasekar et al. 2009). Similarly, in two
Trichinella species, TCTP was reported to be heat-induced (Mak et al. 2001,
2007), indicating that it is involved in cyto-protection under heat-shock conditions.
A study on TCTP in two nematode species, Ostertagia ostertagi, a parasitic
nematode in cattle, and in the free-living nematode Caenorhabditis elegans
revealed that in both species, TCTP was predominantly located in the eggs of the
animals (Meyvis et al. 2009). Interestingly, knock-down of TCTP in C. elegans
reduced the number of eggs laid by the hermaphrodite in the F0 generation by 90%,
indicating that TCTP plays a pivotal role in nematode reproduction.

4.3.3.3

TCTP in Crustaceans and Other Waterborne Animals

Among crustaceans, the TCTP protein most widely studied was in several species
of shrimp, usually by researchers from the Southeast Asian region, predominantly
Thailand. This is because the shrimp industry plays a substantial role in the
economy of this region. One of the major threats to shrimps is the white spot
syndrome virus (WSSV), and several papers show that shrimp TCTP is involved in
immune defence of the animals against the virus. One of the earliest papers on
shrimp TCTP reported already that TCTP levels are severely down-regulated in the
advanced stages of viral infection, compared to early infection stages and
uninfected animals (Bangrak et al. 2004). Subsequently, the same group demonstrated that injection of shrimps with recombinant TCTP/fortilin after infection with
WSSV resulted in 80–100% survival, and it severely reduced the virus load
(Tonganunt et al. 2008). Consistent with this, TCTP/ fortilin of the shrimp Penaeus
monodon inhibited the expression of early and late genes of the WSSV virus in an
insect cell model (Nupan et al. 2011). The group also identified a novel binding
partner to TCTP/fortilin, fortilin-binding protein (FBP1), which might be involved
in the immune defence as well (Panrat et al. 2012).
Recently, a Chinese group working on the TCTP protein of another shrimp
species, Litopenaeus vannamei, reported that TCTP expression was significantly
up-regulated at 16 h and 48 h following infection with the WSSV virus. Silencing of
TCTP with dsRNA led to a significant increase in WSSV loads (Wu et al. 2013).
Yet another Chinese group studied the TCTP protein from the sea cucumber
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Stichopus monotuberculatus. They demonstrated the anti-oxidation and heat-shock
protein properties of recombinant TCTP protein, and their data suggested that the
sea cucumber TCTP may also play an important role in the innate immune defence
against bacterial and viral infections (Ren et al. 2014). Most recently, the characterisation of the TCTP protein of the scallop Chlamys farreri (Cf) was published
(Jia et al. 2017). Its expression levels are highly regulated during embryonic
development of the mollusc, and in response to stimulation with PAMPs
(pathogen-associated molecular patterns). Recombinant CfTCTP could induce the
release of histamine from BT-549 cells. These results indicate that TCTP plays a
pivotal role in the embryonic development and immune protection of scallops.

4.3.3.4

TCTP in Arthropods

Similar to the situation in shrimps, the TCTP protein of the silkworm Bombyx mori
(Bm) has attracted special attention, particularly from Chinese researchers,
although the initial characterisation of the mRNA and the gene structure of
BmTCTP was published by a Japanese group (Lee et al. 2004). Later, the Chinese
group studied the role of BmTCTP in gut immunity of the silkworm in more detail
(Wang et al. 2013). They found that BmTCTP is produced in intestinal epithelial
cells and released into the lumen of the gut. The production increases at early time
points during oral microbial infection, but declines later. BmTCTP acts as a multiligand-binding protein; it also functions as an opsonin that promotes phagocytosis
of microorganisms. TCTP induces the production of an antimicrobial peptide via a
signalling pathway, which involves activation of ERK. The authors conclude that
TCTP is a dual-function protein involved in both the cellular and the humoral
immune response of the silkworm. In support of this, the group recently studied the
effect of silencing of TCTP by RNAi in a transgenic silkworm (Hu et al. 2015).
They reported that the antimicrobial capacity of the silkworm decreased, since the
expression of the gut antimicrobial peptide was not sufficiently induced during
microbial challenge. This led to the suppression of the innate intestinal immunity,
as result of RNAi-mediated knockdown of TCTP.
In summary, the results described in the last two sections show that TCTP is
involved not only in cellular defence mechanisms, such as protection against
oxidation or heat-shock, but also in innate immunity, of both mammals and the
lower taxa of the animal kingdom. A recent, very unusual addition to the various
biological roles of the TCTP protein represents a more ‘aggressive’ one, i.e. the
participation in the deadly cocktail of spider venoms. Two papers reported that
translationally controlled tumour protein is a component of the venom from the
brown spider Loxosceles intermedia (Gremski et al. 2014; Sade et al. 2012).
Another one investigated the spit (used to ‘glue’ the prey to a solid surface) and
the venom of the spider Scytodes thoracica using transcriptomic and proteomic
analyses. In these secretions, they detected TCTP alongside 19 different groups of
toxic peptides (Zobel-Thropp et al. 2014).
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TCTP in Other (Patho)physiological Processes

Apart from being involved in cancer and, as an extracellular protein, in inflammatory and immune reactions, TCTP also participates in other physiological processes
and, if deregulated, in pathologic derailments of these. Known examples will be
summarised in this section.

4.3.4.1

Metabolic Regulation and Diabetes

About five years ago, we studied the regulation and protective role of TCTP in
pancreatic β-cells and demonstrated that TCTP levels are up-regulated in response
to stimulatory glucose concentrations, but down-regulated in stress conditions
induced by fatty acids (palmitate). Overexpression of TCTP prevented cell death
induced by palmitate (Diraison et al. 2011). These results imply that TCTP protects
β-cells against stress induced by hyperglycaemia and by high concentrations of
fatty acids. More recently, Tsai and colleagues studied the effect of TCTP levels on
β-cell proliferation in mice (Tsai et al. 2014). They found that (1) TCTP expression
levels are increased under conditions of enhanced β-cell proliferation, i.e. in the
perinatal development period and in insulin-resistant states (induced by high-fat
diet); (2) TCTP-knockout resulted in decreased β-cell proliferation and cell mass,
and in reduced insulin production, eventually leading to hyperglycaemia. Together,
these two papers highlight the importance of TCTP for maintaining the homeostasis
of pancreatic β-cells and reducing the risk of developing hyperglycaemia and
eventually type 2 diabetes.
Whilst in the case of β-cells, the growth-promoting activity of TCTP helps to
maintain metabolic homeostasis; in other cell types it may contribute to pathological alterations caused by diabetes. An example is provided through a paper by Kim
et al. on podocyte hypertrophy, one of the renal pathologies induced by diabetes
(Kim et al. 2012b). They reported that TCTP levels are increased in the glomeruli of
diabetic mice, compared to control animals. Knockdown of TCTP led to reduced
activity of the mTORC1 pathway in diabetic glomeruli; it reduced the size of the
podocytes and prevented the development of diabetic nephropathy.
Very recently, Goodman and colleagues studied the involvement of TCTP and
the mTOR signalling pathway in physiological models of skeletal muscle hypertrophy and atrophy (Goodman et al. 2017). Their results show that TCTP and mTOR
signalling are up-regulated in both hypertrophy and atrophy of skeletal muscle. The
increase in TCTP observed under these conditions occurred in part via an mTORdependent mechanism. However, the overexpression of TCTP was not sufficient to
activate mTOR signalling. The authors provide preliminary evidence to show that
TCTP may act through inhibiting protein degradation, rather than activation of
protein synthesis.
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Blood Circulation

There are also pathologies of the cardiovascular system that are being promoted
through TCTP. First, a paper by Kyunglim Lee’s group reported that a transgenic
mouse overexpressing TCTP develops systemic hypertension (Kim et al. 2008a).
These authors had previously shown that TCTP inhibits the Na/K-ATPase, and they
proposed that promotion of hypertension by TCTP operates through this
mechanism.
A different disease, despite its similar name, is pulmonary arterial hypertension
(PAH). It is a lethal disease, caused by excessive proliferation of pulmonary
vascular endothelial cells. The hereditary form (HPAH) is often caused by mutations in the bone morphogenetic protein receptor type 2 gene (BMPR2). Lavoie
et al., through a proteomics screen, comparing HPAH patients with BMPR2
mutations with healthy control subjects, identified TCTP as one of 22 significantly
altered proteins (Lavoie et al. 2014). They reported that TCTP is markedly
up-regulated in remodelled blood vessels of complex lesions in lungs from patients
with PAH. Silencing of TCTP expression increased apoptosis and abrogated the
hyperproliferative phenotype of epithelial cells from patients with HPAH.
Also in the case of atherosclerosis, TCTP seems to play a disease-promoting
role, albeit through a different mechanism. Ken Fujise’s group has generated a
mouse model with heterozygous deficiency of TCTP/fortilin in a background of
hypercholesterolemia, which develops atherosclerotic characteristics, similar to
those in humans (Pinkaew et al. 2013). Studying this animal model, they arrived
at the conclusion that TCTP/fortilin acts by reducing apoptosis in macrophages, one
of the main players in the development of atherosclerosis. On the other hand, based
on experiments using TCTP overexpression in ApoE-knockout mice, Kyunglim
Lee’s group proposed that TCTP enhances the severity of atherosclerotic lesions
through the induction of hypertension (Cho et al. 2012).
Taken together, the examples of TCTP’s involvement in diseases given in
Sect. 4.3.4 are by and large based on the growth-promoting effect of TCTP in quite
different cellular settings. In one case (pancreatic β-cells), the net effect of TCTP is
beneficial; in most other cases, it is disease promoting. All examples—inclusive of
cancer—show that, whilst TCTP is generally a cytoprotective protein, its excessive
up-regulation is likely to cause disease. Therefore, understanding the regulation of
TCTP at the cellular level (see following section) is essential for exploring the
mechanisms of such diseases and eventually for our ability to modulate them.
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Regulation of Cellular TCTP Levels
Cell Physiologic Conditions That Result in Regulation
of TCTP Levels

Considering the sheer number and range of cell biological processes TCTP is
involved in (see Sect. 4.2), it is not surprising that cellular levels of the protein
are highly regulated, in response to many different environmental cues and also
through a variety of regulatory mechanisms. Presumably, a large number of
researchers, who today work on TCTP, originally discovered the protein either in
an interaction screen (see Table 4.1), or in search of genes/proteins that are
regulated in defined alterations of physiologic conditions, or during transition to a
disease state. Typically, TCTP is among those proteins, which display the most
prominent changes.
Table 4.3 provides a list of publications, which reported alterations of intracellular TCTP levels in response to altered cell physiologic conditions. The Table lists
the type of signals for adaptation (‘Stimulus’), the cellular system observed and the
likely regulatory mechanism involved. Within the scope of this chapter, it is
impossible to discuss each of these cases, and the reader is referred to the individual
reference for further details. For this table, I have included only those specific cases
of cancer, where a specific mechanism of TCTP up-regulation has been described.
The other examples of TCTP overexpression in cancer are listed in Table 4.2.
Two general points emerge from this compilation: (1) The type of physiological
settings/adaptations that result in regulation of cellular TCTP levels largely correspond to those conditions, where TCTP was shown to be involved, either as
promoting or as protective protein (compare Sect. 4.2.1 to 4.2.3). (2) A whole
range of regulatory mechanisms may be involved in regulating TCTP levels,
i.e. transcriptional or translational regulation, or stability regulation of TCTP
mRNA or protein. However, since not all of the papers listed went into detail to
prove or disprove the one or other option, the overall picture is incomplete and may
look biased towards transcriptional or translational control. Further work will be
necessary to refine this list and confirm or disprove certain types of regulatory
mechanisms.

4.4.2

Mechanisms Involved in Regulation of Cellular TCTP
Levels

In this section, I will only discuss those papers which explored the mechanisms and
signalling pathways that underlie the adaptation of TCTP levels in specific cell
physiologic settings, not those which just report altered TCTP protein or mRNA
levels.
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Table 4.3 Cell physiologic conditions resulting in alterations of TCTP levels
Stimulus
Growth signals:
Serum
Serum
Serum
Serum
Liver
regeneration
Serum starvation
Hypertrophy/
Atrophy
Cell cycle:
Mitotic exit
Cell signalling:
Phorbol ester
M-CSF
Cell differentiation
Nutrients:
Glucose
Fatty acids
Ammonium
starvation
Heat shock

Oxidative stress:
strong: ATO
(mild) H2O2
(mild) H2O2
H2O2

Cell/tissue type
Swiss 3T3 cells

Change
Up

Ehrlich ascites
cells
NIH 3T3 cells

Up

HeLa, HT29
cells
Rat liver

Up

MEF cells

Down

Mouse muscle

Up

Xenopus
embryos
T24 carcinoma
cells
Mouse
macrophages
Mouse erythroleukaemia cells
Pancreatic
β-cells
Pancreatic
β-cells
Yeast

Down

Prostate cancer
cells
Schistosoma;
human
Trichinella
spiralis
Trichinella
pseudospiralis
Cancer cells

Up

Up

Up
Up
Up
Up
Down
Down
(Up)
Up
Up
Up
Down

Cancer cells

Up

Human
keratinocytes
Plant stresses

Up
Up

Mechanism
involved
Translational
control
Translational
control
Translational
control (eIF4E)
Translational
(mTORC1)
Transcription
activation
Translation
inhibition (PKR)
Translational
(mTORC1)
Proteasomal
degradation
Transcription
activation
Increased mRNA
and protein
Transcription
activation
TCTP protein
levels
TCTP protein
levels
Transcription
repression
Hsp27 protects
TCTP protein
Transcription
activation
Transcription
activation
Translational
control
TCTP protein
levels
TCTP protein
levels
Transcription
activation (VDR)
Transcription
activation

References
Thomas et al. (1981),
Thomas and
Thomas (1986)
Bohm et al. (1989,
1991)
Bommer et al. (1994)
Bommer et al. (2015)
Zhu et al. (2008)
Bommer et al. (2002)
Goodman et al. (2017)
Kubiak et al. (2008)
Andree et al. (2006)
Teshima et al. (1998)
Yenofsky et al. (1983)
Diraison et al. (2011)
Diraison et al. (2011)
Bonnet et al. (2000)
Baylot et al. (2012)
Gnanasekar et al. (2009)
Mak et al. (2001)
Mak et al. (2007)
Lucibello et al. (2011)
Lucibello et al. (2011)
Rid et al. (2010)
Chen et al. (2014b)
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Table 4.3 (continued)
Stimulus
Ca(2+)-Stress:
A23187;
Thapsigargin
A23187;
Thapsigargin
Thapsigargin

Cell/tissue type
Cos-7 cells

Change
Up

MEF cells;
β-cells
Pancreatic
β-cells
Human cells

Down

Hepatocellular
cancer (HCC)
Oral cancer cells

Up

NF1-associated
Tumours
Brain regions

Up

Murine cells

Up

Breast cancer
cells
RTL6 cells;
Mouse erythroleukemia cells
U2OS cells

Down

Up
Up

Cd, Cu, Pb, Zn

Calu-6 and
Cos-7 cells
Calu-6 and
Cos-7 cells
Earth worms

Uranium nitrate

Mouse kidneys

Up

Aluminium stress

Up

Salt stress

Soybean
cultivars
Cassava plant

Mercury Stress

Rice roots

Up

Mouse ES cells

Up

Calu-6 and
Cos-7 cells
Earth worms

Up

DNA damage:
γ-Rays
Specific cancer
typesa

Alzheimers;
Down Syndrome
Apoptotic factors:
P53
P53
P53

Depletion of
Mcl-1
Heavy metals:
Copper (Cu)
Cobalt, Nickel

Toxins:
Dioxin
Dioxin
Naphthenic acids

Down
Up

Down

Down

Down

Down

Up

Up

Up

Mechanism
involved
Transcription and
translation

References
Xu et al. (1999)

Translation
inhibition (PKR)
TCTP protein
levels
TCTP protein
levels
Transcription
activ. (CHD1L)
mRNA repression
(miRNA-27b)
Translational
(mTORC1)
Protein levels
decreased
Transcription
activation
P53 inhibits
transcription
P53 reduces
TCTP protein

Bommer et al. (2010)

Protein
degradation
Transcription and
translation
mRNA
stabilisation
Transcription
activation
Transcription and
translation
Transcription
activation
Transcription
activation
TCTP protein
levels
Transcription
activation
Transcription
activation
Transcription
activation

Zhang et al. (2002)

Diraison et al. (2011)
Zhang et al. (2012)
Chan et al. (2012b)
Lo et al. (2012)
Kobayashi et al. (2014)
Kim et al. (2001)
Chen et al. (2013b)
Amson et al. (2012)
Tuynder et al. (2002),
Bommer et al. (2010)

Schmidt et al. (2007)
Schmidt et al. (2007)
Sturzenbaum et al.
(1998)
Taulan et al. (2006)
Ermolayev et al. (2003)
Santa Brigida et al.
(2014)
Wang et al. (2012)
Oikawa et al. (2002)
Schmidt et al. (2007)
Wang et al. (2015)
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Table 4.3 (continued)
Stimulus
Drugs:
5-Fluorouracil
Oxaliplatin
Ursolic acid
Dihydroartemisinin
Dihydroartemisinin
Sertraline,
Thioridazine

Cell/tissue type
Colon cancer
cells
Colon cancer
cells
Hepatocellular
carcinoma cells
Several cell lines

Change
Up

Breast cancer
cells
Breast cancer
cells

Down

Up
Down
Down

Down

Mechanism
involved
Translational
(mTORC1)
Translational
(mTORC1)
Reduced PI3K
signalling
Proteasomal
degradation
Proteasomal
degradation
Increased p53;
mTOR inhibition

References
Bommer et al. (2017)
Bommer et al. (2017),
Yao et al. (2009)
Chuang et al. (2016)
Fujita et al. (2008)
Lucibello et al. (2015)
Amson et al. (2013)

a

Only those cancer types are listed, where the mechanism of TCTP regulation has been explored

4.4.2.1

Transcriptional Regulation of TPT1 Gene Expression

The most comprehensive analysis of the gene structure and transcriptional regulation of the mammalian TPT1 gene came from the Thiele laboratory in Berlin. The
gene and mRNA structures were described in Sect. 4.1.2; here I will just summarise
the results on mechanisms of transcriptional regulation of TCTP expression.
Andree et al. (2006) performed predictions of potential transcription factor-binding
sites in the 50 -flanking region of the TPT1 gene of five mammalian species, which
revealed the conservation of a cluster of five such binding sites within the first
170 nucleotides 50 -terminal to the transcription start site of these genes. These
comprised two binding sites each for the transcription factors ETS1 and CREB and
one binding site for MZF1. In this paper, they confirmed experimentally that TCTP
expression is indeed regulated by phorbol ester (PMA) and forskolin through the
cAMP-PKA signalling pathway via transcription factor CREB.
Other confirmed examples of transcriptional regulation of TCTP synthesis
include the following:
Differentiation of mouse erythroleukaemia (MEL) cells is induced by treatment
of cells with DMSO. It belongs to the very early observations on TCTP (P21)
mRNA that its synthesis increases early in this process, even though its translation
rate decreases after exposure to DMSO (Yenofsky et al. 1983).
Other examples of specific transcriptional regulation of the TPT1 gene are
relevant to cancer: (1) The tumour suppressor protein P53 acts as a transcription
factor and, as an antagonist to TCTP, it binds to a p53-response element upstream of
the TPT1 gene and represses its transcription in human cells (Amson et al. 2012).
This inhibitory activity is alleviated in cancers, which bear mutations in the p53
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gene, as it is frequently the case. (2) In hepatocellular cancer (HCC), a transcription
factor called CHD1L has been identified as a specific oncogene. CHD1L binds to
the promoter region of the TPT1 gene and activates its transcription (Chan et al.
2012b). (3) Transcriptional regulation of TCTP by HIF-1α was reported by Xiao
et al. in colon cancer cells (Xiao et al. 2016). (4) In rat liver regeneration, a model of
actively proliferating tissue, the expression of TCTP mRNA is transiently
up-regulated, from 3 to 12 h after partial hepatectomy (Zhu et al. 2008).
There are also examples of TCTP being transcriptionally regulated in stress
conditions: (1) Mild oxidative stress induced by hydrogen peroxide was reported to
induce transcription activation of TCTP expression through the vitamin D3 receptor
(VDR) in keratinocytes (Rid et al. 2010) and plants (maize) under flood stress
conditions (Chen et al. 2014b). (2) Transcriptional induction of TCTP synthesis by
heavy metals has been observed very early in earthworms (Sturzenbaum et al.
1998). In this case, copper and cadmium led to the highest rates of TCTP mRNA
synthesis. A more detailed study on the regulation of TCTP by heavy metals was
subsequently performed in the Thiele laboratory (Schmidt et al. 2007). They found
that copper induced TCTP synthesis at both the transcriptional and the translational
level, whereas cobalt and nickel seem to result in TCTP mRNA stabilisation. These
authors also showed that the potent toxin dioxin (TCDD) transcriptionally activates
TCTP synthesis in human and Calu-6 and Cos-7 cells, which mirrors an earlier
report on mouse embryonic stem cells (Oikawa et al. 2002).
Further examples of transcriptional activation of TCTP synthesis are given in
Table 4.3.

4.4.2.2

Translational Regulation of TCTP Synthesis

The early demonstration that TCTP is a translationally controlled protein was based
on the following evidence: (1) The rate of synthesis of the proteins ‘Q23’ (Thomas
et al. 1981) and ‘P23’ (Bohm et al. 1989) were found to be increased very early after
serum induction of Swiss 3T3 fibroblasts and mouse Ehrlich ascites tumour cells,
respectively. This rate increase was visible within 10 min, and it was resistant to
inhibition by the transcription inhibitor actinomycin D. (2) These two proteins were
later shown to be identical to yet another one called ‘P21’, the mRNA of which was
found abundantly in cytoplasmic untranslated mRNP particles in mouse sarcoma
ascites cells (Yenofsky et al. 1982). These mRNP particles were considered reserve
pools of untranslated mRNAs.
At the beginning of the 1990s, mechanisms of translational control were just
being unveiled, and the importance of translation initiation factors in cellular
regulation was recognised (reviewed in Clemens and Bommer 1999). In particular,
the ability of the cap-binding protein eIF4E to trigger the malignant transformation
of cells was discovered at this time (Lazaris-Karatzas et al. 1990). The prevailing
hypothesis to explain this crucial role of eIF4E was that certain mRNAs that code
for growth-related proteins are highly structured and are therefore poorly translated.
Overexpression of eIF4E results in more efficient translation of these mRNAs
leading to promotion of cell proliferation. In collaboration with the Sonenberg
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lab, we were able to show that the mRNA of TCTP (P23) is one of the mRNAs, the
translational efficiency of which is highly dependent on eIF4E (Bommer et al.
1994). Consistent with this, we later demonstrated that TCTP(P23) mRNA is
indeed a highly structured molecule (Bommer et al. 2002).
It was only late in the 1990s that the link was established between the PI3K/Akt/
mTORC1 growth signalling pathway and the activation of eIF4E via phosphorylation of the inhibitory eIF4E-binding proteins, 4E-BPs (Clemens and Bommer 1999).
Also, it became increasingly clear that a subset of mRNAs, i.e. the ones bearing a
50 -terminal oligopyrimidine tract (50 -TOP), is specifically regulated through this
pathway. The main representatives of this group of mRNAs are those which encode
components of the translational apparatus (Meyuhas and Kahan 2015). Since the
TCTP mRNA also features a 50 -TOP (Yamashita et al. 2008), we recently revisited
this topic and showed that the growth factor-dependent induction of TCTP synthesis
is indeed regulated through the PI3K/Akt/mTORC1 pathway and eIF4E (Bommer
et al. 2015). We also found that treatment of colon cancer cells with DNA-damaging
anticancer drugs leads to a four-fold up-regulation of TCTP levels through the
mTORC1 pathway (Bommer et al. 2017). Similarly, Goodman et al. reported an
increase in TCTP levels in muscle hypertrophy and atrophy and its regulation
through mTOR signalling (Goodman et al. 2017).
An important negative translational control mechanism operates via phosphorylation of translation initiation factor eIF2α. This phosphorylation event prevents
the recycling of the guanosine nucleotide exchange factor for eIF2, eIF2B, and
results in the shutdown of protein synthesis. There are four specific protein kinases
that are able to phosphorylate eIF2α, each one being activated under very specific
cell stress conditions (Clemens and Bommer 1999). One of these, the dsRNAdependent kinase PKR, is an antiviral enzyme that is activated by double-stranded
RNA, which is often formed during viral replication. However, there are also few
cellular mRNAs, which are highly structured and able to activate PKR. We have
shown that the mRNA for TCTP is one of those mRNA molecules. Due to its
structure, it can activate PKR locally and prevent its own translation (Bommer et al.
2002). We have also demonstrated that TCTP mRNA translation is indeed inhibited
by PKR in cell stress conditions, as, e.g. in serum starvation (Bommer et al. 2002)
or under calcium stress (Bommer et al. 2010).
These findings are consistent with reports on the regulation of other antiapoptotic proteins, such as Mcl-1, Bcl-XL and survivin. They are all translationally
regulated through the mTORC1 pathway [see references in Bommer et al. (2015)],
and Mcl-1 is also regulated through PKR (Fritsch et al. 2007).

4.4.2.3

Other Post-transcriptional Regulation

1. Regulation by Micro-RNAs. The expression of genes involved in fundamental
biological processes, such as development, apoptosis or cancer, are often subject
to an additional layer of regulation, by micro-RNAs. This also applies to antiapoptotic proteins, as they are mentioned above. It is, therefore, appropriate to
assume that TCTP would be regulated by micro-RNAs as well. However, reports
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on this topic are scarce in the literature; in fact, there are only two papers from
2012 reporting the regulation of TCTP levels by micro-RNAs.
Lo et al. performed a proteomics study on genes differentially expressed in
oral cancer patients compared to normal individuals; they found TCTP to be
up-regulated in the cancer patient group (Lo et al. 2012). At the same time, the
miRNA miR-27b was down-regulated in oral cancer, and expression of miR-27b
in two oral cancer cell lines resulted in TCTP levels being reduced to about 30%.
In a study to validate an assay for miRNA target identification, Gäken and
colleagues used miR-130a as an example. They reported TCTP as the one of
the five target mRNAs newly identified by this method, which is regulated to the
highest extent (Gaken et al. 2012).
We ourselves attempted to identify micro-RNAs that may target TCTP
mRNA. In-silico searches revealed several potential target sites in the 30 -UTR
of this mRNA; however, our attempts to validate some of these in luciferase
reporter gene and in cellular assays did not yield consistent results (UA Bommer,
J Clancy and T. Preiss, unpublished observations), and we did not pursue this
project further. Thus, the only two reported cases of miRNAs targeting TCTP
mRNA are miR-27b and miR-130a.
2. Regulation of mRNA stability. In their study on the regulation of TCTP expression by heavy metals, Schmidt et al. found that cobalt and nickel moderately
increase TCTP expression through stabilisation of its mRNA (Schmidt et al.
2007). They speculated about the potential role of AUUUA motifs in the 30 -UTR
of TCTP mRNA in this process. However, these AUUUA elements do not
completely match the ‘classical’ AU-rich elements (AREs), which in cytokine
mRNAs serve to target these RNAs for regulated degradation. The role of these
motifs in TCTP mRNA, if any, is yet to be elucidated. Overall, TCTP mRNA
was found to be generally fairly stable and abundant in mammalian cells
(Yenofsky et al. 1983), although the abundance varies depending on the tissue
type (Thiele et al. 2000). Our finding that TCTP mRNA has a high degree of
structure (Bommer et al. 2002) is also consistent with the notion that it is a fairly
stable RNA molecule.
3. Protein stability regulation. There are a few reports, which indicate that in
specific instances TCTP protein may be subject to regulated degradation. Two
studies described the ability of another anti-apoptotic protein, Mcl-1 (Zhang
et al. 2002), and heat-shock protein Hsp27 (Baylot et al. 2012) to stabilise the
TCTP protein, which implies that it may be destabilised if those proteins are
absent. Kubiak et al. reported that TCTP, a protein involved in maintaining the
integrity of the mitotic spindle, is partially degraded during mitotic exit (Kubiak
et al. 2008). A novel mechanism for regulated degradation of TCTP protein was
published in a very recent paper (see ‘Note Added in Proof’).
In summary, TCTP levels can be regulated at all levels of gene expression,
inclusive of protein stability, although transcriptional and translational regulation
of protein expression seems to be the most commonly reported regulatory
mechanisms.
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Synopsis

During the 35 years since its original discovery, the translationally controlled
tumour protein TCTP has attracted an ever-increasing level of attention. Through
a body of well over 300 publications as of today, a considerable number of
functional associations of this protein have been established.
Although TCTP is largely a cellular protein, it has also extracellular functions,
and its importance in fundamental biological processes often has implications for
homeostasis at the whole-organism level. In trying to summarise the functional
importance of this protein, the following key words come to mind: cell growth and
proliferation, early development, cyto-protection and defence. Many examples
studied by today confirm that TCTP is involved in the biological defence against
a wide range of cell stresses, in nearly all eukaryotic kingdoms. The specifics of the
defence reactions, in which TCTP is engaged, may be quite varied between lower
and higher organisms or between plants and animals. What we need now is a deeper
understanding of the mechanisms, by which TCTP exerts all these effects.
Naturally, the involvement in these important processes requires a high degree
of regulation of both levels and activity of the protein. We do understand some of
the underlying mechanisms, but by far not yet all details. Such understanding is of
particular importance, since the frequent participation of TCTP in disease processes, such as in cancer, is often due to deregulation of TCTP or due to the exertion
of its effects at the wrong time in the wrong place. Promising initial discoveries
have been made, identifying TCTP as a potential target in anticancer (or other
disease) strategies. We have to learn more about some of the functional interactions
of this protein, as well as its regulation, in order eventually to be able to translate
this knowledge into meaningful clinical application.
Note Added in Proof
Since the original completion of this manuscript (December 2016) more than half a
year has passed, and quite a few new papers on the TCTP protein were published in
the meantime. Of these, I just wish to mention the following five publications,
which added some interesting new aspects to our understanding of the biology of
this protein. (My apology to those colleagues, whose work was not considered here,
or even in the main manuscript!)
1. As pointed out in Sect. 4.2.1, there are a large number of publications reporting
TCTP as a cyto-protective protein, able to protect cells against a wide range of
cytotoxic stresses, inclusive of Ca2+-stress. However, so far, an involvement of
TCTP in modulating ER-stress and the unfolded protein response (UPR) was
not yet described. A recent paper by Pinkaew et al. fills this gap (Pinkaew et al.
2017), by reporting that TCTP (fortilin) binds to the cytoplasmic domain of the
ER-stress sensor IRE1α, inhibiting its endonuclease (RNase) and protein kinase
activities, and in this way protecting cells against apoptotic cell death.
2. The involvement of TCTP in the cellular process of autophagy was studied in a
recent paper by the group of Kyunglim Lee (Bae et al. 2017). They found that
TCTP interferes with this process in both the mTORC1/AMPK-dependent and
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the mTORC1-independent pathway. Thus, TCTP inhibits macroautophagy both
at early stages and later at the step of autophagosome maturation. This conclusion contrasts that of another paper (Chen et al. 2014a), cited in Sect. 4.2.3. A
possible explanation for this discrepancy is given in the discussion of the more
recent paper (Bae et al. 2017).
3. In the very last section of the main text, I mentioned that relatively little is
known about the mechanisms involved in regulation of TCTP degradation.
This gap was closed by a very recent paper by Bonhoure et al. (2017), who
showed that TCTP protein can be degraded through the chaperone-mediated
autophagy (CMA) pathway. This pathway is different from the process of
macroautophagy mentioned in the preceding paragraph. CMA involves the
targeting of individual cytoplasmic proteins for lysosomal degradation. In the
case of TCTP, it involves the acetylation of the protein at Lysine 19 and its
binding to Hsc70, and it requires the activity of lysosome-associated membrane
protein type 2A (LAMP-2A). The authors show that this is an underlying
mechanism for the down-regulation of TCTP levels under serum-starvation
conditions (Bonhoure et al. 2017), which is likely to be corroborated by a
block in TCTP mRNA translation (Bommer et al. 2002, 2015).
4. Previous studies on the role of TCTP in plants, other than in stress reactions,
showed that plant TCTP is important for cell division, growth and development
(Sect. 4.2.3). A new study extended these investigations. De Carvalho and colleagues expressed tomato TCTP in tobacco plants and, by transcriptomics analysis,
studied the pathways that are differentially regulated as a result of TCTP
overexpression (de Carvalho et al. 2017). They observed that genes involved in
photosynthesis, fatty acid metabolism and water transport are up-regulated, while
genes involved in the synthesis of the phytohormone ethylene were downregulated. TCTP overexpression also promoted biomass production and it protected
plants against salt and osmotic stress. These observations are also consistent with an
earlier study that demonstrated the ability of Arabidopsis thaliana TCTP to protect
tobacco leafs against induction of programmed cell death (Hoepflinger et al. 2013).
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